cinobufagin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O

cinobufagin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

SB216367 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
apoptosis O
in O
OS O
cells O
were O
also O
observed O
. O
The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β B
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
apoptosis O
in O
OS O
cells O
were O
also O
observed O
. O
The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 B
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 B
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
decrease O
in O
nuclear O
p65 B
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

SB216367 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nuclear O
p65 B
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

furanopyrimidine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
structure O
of O
Aurora O
kinase O
A O
suggests O
the O
potential O
to O
improve O
the O
activity O
of O
the O
ligands O
by O
decreasing O
the O
steric O
clash O
with O
Val147 O
and O
Leu139 O
and O
by O
increasing O
hydrophobic O
contact O
with O
Leu139 O
and O
Gly216 O
residues O
in O
the O
solvent-exposed O
region O
of O
the O
enzyme O
. O
Based O
on O
these O
suggestions O
, O
the O
rational O
redesign O
of O
furanopyrimidine O
24 O
(clog O
P=7.41; O
Aurora O
A O
IC(50) O
=43 O
nM; O
HCT-116 O
IC(50) O
=400 O
nM) O
led O
to O
the O
identification O
of O
quinazoline O
67 O
(clog O
P=5.28; O
Aurora O
A O
IC(50) O
=25 O
nM; O
HCT-116 O
IC(50) O
=23 O
nM) O
. O
Rat O
in O
vivo O
pharmacokinetic O
studies O
showed O
that O
67 O
has O
better O
systemic O
exposure O
after O
i.v O
. O
administration O
than O
24 O
, O
and O
holds O

quinazoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
steric O
clash O
with O
Val147 O
and O
Leu139 O
and O
by O
increasing O
hydrophobic O
contact O
with O
Leu139 O
and O
Gly216 O
residues O
in O
the O
solvent-exposed O
region O
of O
the O
enzyme O
. O
Based O
on O
these O
suggestions O
, O
the O
rational O
redesign O
of O
furanopyrimidine O
24 O
(clog O
P=7.41; O
Aurora O
A O
IC(50) O
=43 O
nM; O
HCT-116 O
IC(50) O
=400 O
nM) O
led O
to O
the O
identification O
of O
quinazoline O
67 O
(clog O
P=5.28; O
Aurora O
A O
IC(50) O
=25 O
nM; O
HCT-116 O
IC(50) O
=23 O
nM) O
. O
Rat O
in O
vivo O
pharmacokinetic O
studies O
showed O
that O
67 O
has O
better O
systemic O
exposure O
after O
i.v O
. O
administration O
than O
24 O
, O
and O
holds O
potential O
for O
further O
development O
. O

pyrazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
a O
potent O
quinazoline-based O
Aurora O
kinase O
inhibitor.We O
describe O
the O
3D-QSAR-assisted O
design O
of O
an O
Aurora O
kinase O
A O
inhibitor O
with O
improved O
physicochemical O
properties O
, O
in O
vitro O
activity O
, O
and O
in O
vivo O
pharmacokinetic O
profiles O
over O
those O
of O
the O
initial O
lead O
. O
Three O
different O
3D-QSAR O
models O
were O
built O
and O
validated O
by O
using O
a O
set O
of O
66 O
pyrazole O
(Model O
I) O
and O
furanopyrimidine O
(Model O
II) O
compounds O
with O
IC(50) O
values O
toward O
Aurora O
kinase O
A O
ranging O
from O
33 O
nM O
to O
10.5 O
μM O
. O
The O
best O
3D-QSAR O
model O
, O
Model O
III O
, O
constructed O
with O
24 O
training O
set O
compounds O
from O
both O
series O
, O
showed O
robustness O
(r(2) O
(CV) O
=0.54 O
and O
0.52 O
for O
CoMFA O
and O
CoMSIA O
, O
respectively) O
and O

furanopyrimidine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Aurora O
kinase O
inhibitor.We O
describe O
the O
3D-QSAR-assisted O
design O
of O
an O
Aurora O
kinase O
A O
inhibitor O
with O
improved O
physicochemical O
properties O
, O
in O
vitro O
activity O
, O
and O
in O
vivo O
pharmacokinetic O
profiles O
over O
those O
of O
the O
initial O
lead O
. O
Three O
different O
3D-QSAR O
models O
were O
built O
and O
validated O
by O
using O
a O
set O
of O
66 O
pyrazole O
(Model O
I) O
and O
furanopyrimidine O
(Model O
II) O
compounds O
with O
IC(50) O
values O
toward O
Aurora O
kinase O
A O
ranging O
from O
33 O
nM O
to O
10.5 O
μM O
. O
The O
best O
3D-QSAR O
model O
, O
Model O
III O
, O
constructed O
with O
24 O
training O
set O
compounds O
from O
both O
series O
, O
showed O
robustness O
(r(2) O
(CV) O
=0.54 O
and O
0.52 O
for O
CoMFA O
and O
CoMSIA O
, O
respectively) O
and O
superior O
predictive O
capacity O
for O

quinazoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
3D-QSAR-assisted O
drug O
design O
: O
identification O
of O
a O
potent O
quinazolin O
-based O
Aurora B
kinase I
inhibitor.We O
describe O
the O
3D-QSAR-assisted O
design O
of O
an O
Aurora O
kinase O
A O
inhibitor O
with O
improved O
physicochemical O
properties O
, O
in O
vitro O
activity O
, O
and O
in O
vivo O
pharmacokinetic O
profiles O
over O
those O
of O
the O
initial O
lead O
. O
Three O
different O
3D-QSAR O
models O
were O
built O
and O
validated O
by O
using O
a O
set O
of O
66 O
pyrazole O
(Model O
I) O

arginine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O

arginine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc B
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O

arginine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O

JY-3-094 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc B
inhibitory O
activity O
further O
still O
. O

JY-3-094 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc O
inhibitory O
activity O
further O
still O
. O

JY-3-094 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc O
inhibitory O
activity O
further O
still O
. O

JY-3-094 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc O
inhibitory O
activity O
further O
still O
. O

10074-G5 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O

N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
( O
N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O

10074-G5 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc B
inhibitor O
10074-G O
.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O

JY-3-094 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc B
inhibitory O
activity O
further O
still O
. O

10074-G5 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc B
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O

10074-G5 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O

N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc B
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
( O
N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O

N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
( O
N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O

paraoxon O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
preventing O
entry O
into O
the O
circulation O
and O
inhibition O
of O
plasma O
BChE O
and O
AChE O
on O
red O
blood O
cells O
(RBC-AChE) O
and O
in O
cholinergic O
synapses O
. O
In O
contrast O
to O
parenteral O
delivery O
of O
rBChE O
, O
which O
currently O
requires O
posttranslational O
modification O
for O
good O
plasma O
stability O
, O
an O
unmodified O
aer-rBChE O
pretreatment O
given O
1-40h O
prior O
to O
>1 O
LD50 O
of O
aer- O
paraoxon O
(Px) O
was O
able O
to O
prevent O
inhibition O
of O
circulating O
cholinesterase B
in O
a O
dose-dependent O
manner O
. O
These O
studies O
are O
the O
first O
to O
show O
protection O
by O
rBChE O
against O
a O
pesticide O
such O
as O
paraoxon O
when O
delivered O
directly O
into O
the O
lung O
and O
bode O
well O
for O
the O
use O
of O
a O
non-invasive O
and O
consumer O
friendly O
method O
of O

Ozone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ozone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ozone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ozone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH B
and O
MDA O
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ozone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD B
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Pak1(-/-) O
mice O
, O
associated O
with O
impaired O
glucose O
tolerance O
after O
an O
ip O
or O
oral O
glucose O
challenge O
. O
These O
mice O
had O
lower O
circulating O
active O
GLP-1 O
levels O
after O
a O
glucose O
challenge O
as O
well O
as O
reduced O
distal O
ileum O
GLP-1 O
content O
after O
insulin O
treatment O
. O
Finally O
, O
the O
Pak1(-/-) O
mice O
exhibited O
reduced O
brainstem O
gcg O
level O
and O
abolished O
β-cat B
Ser O
75 O
phosphorylation O
in O
brain O
neurons O
after O
insulin O
treatment O
. O
We O
suggest O
that O
Pak1 O
mediates O
the O
cross O
talk O
between O
insulin O
and O
Wnt O
signaling O
pathways O
on O
gut O
and O
brain O
gcg O
expression O
, O
and O
its O
ablation O
impairs O
glucose O
homeostasis O
. O

Thr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
proglucagon O
(gcg) O
expression O
and O
glucagon-like O
peptide-1 O
(GLP-1) O
production O
. O
In O
several O
other O
cell O
lineages O
, O
insulin O
is O
able O
to O
stimulate O
p21-activated O
protein O
kinase O
1 O
(Pak1) O
. O
Here O
we O
determined O
the O
role O
of O
Pak1 B
in O
gcg O
expression O
and O
the O
effect O
of O
Pak1 O
deletion O
on O
glucose O
homeostasis O
. O
Insulin O
stimulated O
Pak1 O
activation O
through O
increasing O
its O
Thr O
23 O
phosphorylation O
in O
gut O
gcg-expressing O
cell O
lines O
, O
associated O
with O
increased O
gcg O
mRNA O
levels O
. O
This O
stimulation O
was O
attenuated O
by O
the O
Pak O
inhibitor O
2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
(IPA3) O
or O
dominant-negative O
Pak1 O
. O
Both O
insulin O
and O
cAMP-promoting O
agents O
activated O
β-cat O
Ser675 O
phosphorylation O
, O
which O
was O
attenuated O
by O
IPA3 O
or O
protein O
kinase O
A O
inhibition O
, O
respectively O
. O
Gut O
gcg O
levels O

2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
1 O
(Pak1) O
. O
Here O
we O
determined O
the O
role O
of O
Pak1 O
in O
gcg O
expression O
and O
the O
effect O
of O
Pak1 O
deletion O
on O
glucose O
homeostasis O
. O
Insulin O
stimulated O
Pak1 O
activation O
through O
increasing O
its O
Thr423 O
phosphorylation O
in O
gut O
gcg-expressing O
cell O
lines O
, O
associated O
with O
increased O
gcg O
mRNA O
levels O
. O
This O
stimulation O
was O
attenuated O
by O
the O
Pak B
inhibitor O
2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
(IPA3) O
or O
dominant-negative O
Pak1 O
. O
Both O
insulin O
and O
cAMP-promoting O
agents O
activated O
β-cat O
Ser675 O
phosphorylation O
, O
which O
was O
attenuated O
by O
IPA3 O
or O
protein O
kinase O
A O
inhibition O
, O
respectively O
. O
Gut O
gcg O
levels O
were O
reduced O
in O
male O
Pak1(-/-) O
mice O
, O
associated O
with O
impaired O
glucose O
tolerance O
after O
an O
ip O
or O
oral O
glucose O
challenge O
. O
These O
mice O
had O
lower O

IPA3 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Here O
we O
determined O
the O
role O
of O
Pak1 O
in O
gcg O
expression O
and O
the O
effect O
of O
Pak1 O
deletion O
on O
glucose O
homeostasis O
. O
Insulin O
stimulated O
Pak1 O
activation O
through O
increasing O
its O
Thr423 O
phosphorylation O
in O
gut O
gcg-expressing O
cell O
lines O
, O
associated O
with O
increased O
gcg O
mRNA O
levels O
. O
This O
stimulation O
was O
attenuated O
by O
the O
Pak B
inhibitor O
2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
( O
IPA3 O
or O
dominant-negative O
Pak1 O
. O
Both O
insulin O
and O
cAMP-promoting O
agents O
activated O
β-cat O
Ser675 O
phosphorylation O
, O
which O
was O
attenuated O
by O
IPA3 O
or O
protein O
kinase O
A O
inhibition O
, O
respectively O
. O
Gut O
gcg O
levels O
were O
reduced O
in O
male O
Pak1(-/-) O
mice O
, O
associated O
with O
impaired O
glucose O
tolerance O
after O
an O
ip O
or O
oral O
glucose O
challenge O
. O
These O
mice O
had O
lower O
circulating O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
FUT9) O
to O
selectin-ligand O
biosynthesis O
were O
evaluated O
. O
The O
cell O
adhesion O
properties O
of O
these O
modified O
cells O
to O
L- O
, O
E- O
, O
and O
P-selectin O
under O
hydrodynamic O
shear O
were O
compared O
with O
bone O
marrow-derived O
neutrophils O
from O
Fut4(-/-)Fut7(-/-) O
dual O
knock-out O
mice O
. O
Results O
demonstrate O
that O
predominantly O
FUT7 O
, O
and O
to O
a O
lesser O
extent O
FUT4 O
, O
forms O
the O
selectin-ligand O
at O
the O
N O
terminus O
of O
leukocyte O
P-selectin B
glycoprotein I
ligand-1 I
(PSGL-1) O
in O
humans O
and O
mice O
. O
Here O
, O
85% O
reduction O
in O
leukocyte O
interaction O
was O
observed O
in O
human O
FUT4(-)7(-) O
dual O
knockdowns O
on O
P/L-selectin O
substrates O
. O
Unlike O
Fut4(-/-)Fut7(-/-) O
mouse O
neutrophils O
, O
however O
, O
human O
knockdowns O
lacking O
FUT4 O
and O
FUT7 O
only O
exhibited O
partial O
reduction O
in O
rolling O
interaction O
on O
E-selectin O
. O
In O
this O

α-MeDA O
acts O
as O
NOT O
for O
what O
entity O
? O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O
scavenger O
, O
tiron O
, O
nor O
the O
inhibitor O
of O
the O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α- O
MeDA O
s O
owed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine B
synthetase I
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BSO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O

α-MeDA O
acts O
as O
NOT O
for O
what O
entity O
? O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O
scavenger O
, O
tiron O
, O
nor O
the O
inhibitor O
of O
the O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α- O
MeDA O
s O
owed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BSO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O

MDMA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
contributors O
for O
MDMA O
neurotoxicity O
. O
This O
work O
studied O
the O
neurotoxicity O
of O
MDMA O
and O
its O
catechol O
metabolites O
, O
α-methyldopamine O
(α-MeDA) O
and O
N-methyl-α-methyldopamine O
(N-Me-α-MeDA) O
in O
human O
dopaminergic O
SH-SY5Y O
cells O
differentiated O
with O
retinoic O
acid O
and O
12-O-tetradecanoyl-phorbol-13-acetate O
. O
Differentiation O
led O
to O
SH-SY5Y O
neurons O
with O
higher O
ability O
to O
accumulate O
dopamine O
and O
higher O
resistance O
towards O
dopamine O
neurotoxicity O
. O
MD O
MA O
c O
techol O
metabolites O
were O
neurotoxic O
to O
SH-SY5Y O
neurons O
, O
leading O
to O
caspase O
3-independent O
cell O
death O
in O
a O
concentration- O
and O
time-dependent O
manner O
. O
MDMA O
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O

catechol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
for O
MDMA O
neurotoxicity O
. O
This O
work O
studied O
the O
neurotoxicity O
of O
MDMA O
and O
its O
catechol O
metabolites O
, O
α-methyldopamine O
(α-MeDA) O
and O
N-methyl-α-methyldopamine O
(N-Me-α-MeDA) O
in O
human O
dopaminergic O
SH-SY5Y O
cells O
differentiated O
with O
retinoic O
acid O
and O
12-O-tetradecanoyl-phorbol-13-acetate O
. O
Differentiation O
led O
to O
SH-SY5Y O
neurons O
with O
higher O
ability O
to O
accumulate O
dopamine O
and O
higher O
resistance O
towards O
dopamine O
neurotoxicity O
. O
MDMA O
ca O
techol O
m O
tabolites O
were O
neurotoxic O
to O
SH-SY5Y O
neurons O
, O
leading O
to O
caspase O
3-independent O
cell O
death O
in O
a O
concentration- O
and O
time-dependent O
manner O
. O
MDMA O
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O

BSO O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BS O
O) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O
not O
augment O
this O
metabolite O
cytotoxicity O
. O
Even O
so O
, O
BSO O
pre-treatment O
abolished O
NAC O
protective O
effects O
against O
α-MeDA O
neurotoxicity O
, O
which O
were O
, O
at O
least O
partially O
, O
due O
to O
GSH O
de O
novo O
synthesis O
. O
Inversely O
, O
pre-treatment O
of O
cells O
with O
BSO O
augmented O
N-Me-α-MeDA-induced O
neurotoxicity O
, O

GBR O
12909 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
death O
in O
a O
concentration- O
and O
time-dependent O
manner O
. O
MDMA O
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O
scavenger O
, O
tiron O
, O
nor O
the O
inhibitor O
of O
the O
dopamine O
(DA) O
transporter O
, O
GB O
R O
12909 O
, O
revented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BSO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O

buthionine O
sulfoximine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
bu O
thionine O
sulfoximine O
( O
SO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O
not O
augment O
this O
metabolite O
cytotoxicity O
. O
Even O
so O
, O
BSO O
pre-treatment O
abolished O
NAC O
protective O
effects O
against O
α-MeDA O
neurotoxicity O
, O
which O
were O
, O
at O
least O
partially O
, O
due O
to O
GSH O
de O
novo O
synthesis O
. O
Inversely O
, O
pre-treatment O
of O
cells O
with O
BSO O
augmented O

sodium O
selenite O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
neonatal O
rats O
before O
eyelid O
opening O
. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA B
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investigated O
. O
The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
(TEM) O
using O
lanthanum O
hydroxide O
as O
tracer O
that O
higher O

sodium O
selenite O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
neonatal O
rats O
before O
eyelid O
opening O
. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investigated O
. O
The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
(TEM) O
using O
lanthanum O
hydroxide O
as O
tracer O
that O
higher O

sodium O
selenite O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
neonatal O
rats O
before O
eyelid O
opening O
. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investigated O
. O
The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
(TEM) O
using O
lanthanum O
hydroxide O
as O
tracer O
that O
higher O

sodium O
selenite O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
neonatal O
rats O
before O
eyelid O
opening O
. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx B
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investigated O
. O
The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
(TEM) O
using O
lanthanum O
hydroxide O
as O
tracer O
that O
higher O

(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 B
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration O
. O
(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O

KCA-1490 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 B
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
( O
KCA-1490 O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N O
alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 B
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N O
alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 B
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O

pyridazinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 B
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O

pyridazinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 B
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O

6-aryl-4,5-dihydropyridazin-3(2H)-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 B
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O

6-aryl-4,5-dihydropyridazin-3(2H)-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 B
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 B
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N O
alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O
that O
suppress O
histamine-induced O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 B
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N O
alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O
that O
suppress O
histamine-induced O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
E2-conjugating O
enzyme O
, O
Ubc12 O
, O
to O
the O
ubiquitin O
ligase O
, O
XIAP O
or O
cIAP1 O
. O
This O
permits O
transfer O
of O
the O
rare O
ubiquitin O
homolog O
NEDD8 O
to O
the O
ubiquitin O
E3 O
substrates O
, O
allowing O
them O
to O
be O
efficiently O
purified O
for O
LC-MS/MS O
identification O
. O
We O
have O
identified O
>50 O
potential O
IAP B
substrates O
of O
both O
cytosolic O
and O
mitochondrial O
origin O
that O
bear O
hallmark O
N O
terminal O
IAP O
binding O
motifs O
. O
These O
substrates O
include O
the O
recently O
discovered O
protein O
phosphatase O
PGAM5 O
, O
which O
we O
show O
is O
proteolytically O
processed O
, O
accumulates O
in O
cytosol O
during O
apoptosis O
, O
and O
sensitizes O
cells O
to O
death O
. O
These O
studies O
reveal O
mechanisms O
and O
antagonistic O
partners O
for O
specific O
IAPs O
, O
and O
provide O
a O
powerful O
technology O
for O
labeling O
binding O
partners O
in O

benzimidazole O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Identification O
of O
a O
novel O
benzimidazol O
derivative O
as O
a O
highly O
potent O
NPY B
Y5 I
receptor I
antagonist O
with O
an O
anti-obesity O
profile.Optimization O
of O
HTS O
hit O
1 O
for O
NPY O
Y5 O
receptor O
binding O
affinity O
, O
CYP450 O
inhibition O
, O
solubility O
and O
metabolic O
stability O
led O
to O
the O
identification O
of O
some O
orally O
available O
oxygen-linker O
derivatives O
for O
in O
vivo O
study O
. O
Among O
them O
, O
derivative O
4i O
inhibited O
food O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
is O
an O
unusual O
specialized O
DNA O
polymerase O
whose O
in O
vivo O
function O
is O
under O
active O
investigation O
. O
POLQ O
has O
been O
implicated O
by O
different O
experiments O
to O
play O
a O
role O
in O
resistance O
to O
ionizing O
radiation O
and O
defense O
against O
genomic O
instability O
, O
in O
base O
excision O
repair O
, O
and O
in O
immunological O
diversification O
. O
The O
protein O
is O
formed O
by O
an O
N O
terminal O
helicase-like O
domain O
, O
a O
C-terminal O
DNA O
polymerase O
domain O
, O
and O
a O
large O
central O
domain O
that O
spans O
between O
the O
two O
. O
This O
arrangement O
is O
also O
found O
in O
the O
Drosophila O
Mus308 O
protein O
, O
which O
functions O
in O
resistance O
to O
DNA O
interstrand O
crosslinking O
agents O
. O
Homologs O
of O
POLQ O
and O
Mus308 O
are O
found O
in O
multicellular O
eukaryotes O
, O
including O
plants O
, O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
DNA O
polymerase O
whose O
in O
vivo O
function O
is O
under O
active O
investigation O
. O
POLQ O
has O
been O
implicated O
by O
different O
experiments O
to O
play O
a O
role O
in O
resistance O
to O
ionizing O
radiation O
and O
defense O
against O
genomic O
instability O
, O
in O
base O
excision O
repair O
, O
and O
in O
immunological O
diversification O
. O
The O
protein O
is O
formed O
by O
an O
N-terminal O
helicase-like O
domain O
, O
a O
C O
terminal O
DNA O
polymerase O
domain O
, O
and O
a O
large O
central O
domain O
that O
spans O
between O
the O
two O
. O
This O
arrangement O
is O
also O
found O
in O
the O
Drosophila O
Mus308 O
protein O
, O
which O
functions O
in O
resistance O
to O
DNA O
interstrand O
crosslinking O
agents O
. O
Homologs O
of O
POLQ O
and O
Mus308 O
are O
found O
in O
multicellular O
eukaryotes O
, O
including O
plants O
, O
but O
a O
comparison O
of O

OMT O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 B
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O
ischemia O
. O

OMT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA B
receptors I
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O
ischemia O
. O

OMT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cerebral O
artery O
occlusion O
and O
a O
24 O
h O
reperfusion O
, O
in O
vivo O
. O
In O
vitro O
cultured O
neurons O
challenged O
with O
N-methyl-D-aspartate O
(NMDA O
, O
200 O
μM) O
for O
30 O
min O
showed O
significant O
decrease O
in O
the O
viability O
of O
neurons; O
however O
, O
OMT O
was O
able O
to O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax B
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O

OMT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
N-methyl-D-aspartate O
(NMDA O
, O
200 O
μM) O
for O
30 O
min O
showed O
significant O
decrease O
in O
the O
viability O
of O
neurons; O
however O
, O
OMT O
was O
able O
to O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B B
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O

OMT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B B
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O
ischemia O
. O

BT-07-4M O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE B
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

TMB-4 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
paraoxon O
and O
tabun O
inhibition O
. O
AChE B
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

obidoxime O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
tabun O
inhibition O
. O
AChE B
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

oximes O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE B
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

BT-05 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE B
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

BT-03 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE B
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

paraoxon O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat O
brain O
AChE B
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O

dichlorvos O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE B
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

dichlorvos O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
reactivators O
against O
OPC O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat B
brain I
AChE I
after O
dichlorvos O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O

paraoxon O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
against O
OPC O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat B
brain I
AChE I
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O

tabun O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat B
brain I
AChE I
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
uptake O
of O
TEA; O
however O
, O
uptake O
of O
phenformin O
into O
mitochondria O
of O
organic O
cation/carnitine O
transporter O
1 O
(OCTN1) O
knockout O
mice O
was O
lower O
than O
that O
in O
wild-type O
mice O
, O
whereas O
uptake O
of O
TEA O
was O
comparable O
between O
the O
two O
strains O
, O
suggesting O
the O
involvement O
of O
distinct O
transport O
mechanisms O
for O
these O
two O
cations O
in O
mitochondria O
. O
Inhibition O
by O
phenformin O
of O
oxygen O
consumption O
via O
complex B
I I
respiration O
in O
isolated O
rat O
liver O
mitochondria O
was O
greater O
than O
that O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex O
I O
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Role O
of O
organic O
cation/carnitine O
transporter O
1 O
in O
uptake O
of O
phenformi O
and O
inhibitory O
effect O
on O
complex B
I I
respiration O
in O
mitochondria.Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O

Phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Role O
of O
organic O
cation/carnitine O
transporter O
1 O
in O
uptake O
of O
phenformin O
and O
inhibitory O
effect O
on O
complex O
I O
respiration O
in O
mitochondria O
. O
Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O
I O
inhibition O
by O
phenformin O
were O
examined O
in O
isolated O
liver O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
whereas O
uptake O
of O
TEA O
was O
comparable O
between O
the O
two O
strains O
, O
suggesting O
the O
involvement O
of O
distinct O
transport O
mechanisms O
for O
these O
two O
cations O
in O
mitochondria O
. O
Inhibition O
by O
phenformin O
of O
oxygen O
consumption O
via O
complex B
I I
respiration O
in O
isolated O
rat O
liver O
mitochondria O
was O
greater O
than O
that O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex O
I O
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O
was O
weaker O
in O
octn1(-/-) O
mice O
than O
that O
in O
wild-type O
mice O
. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin O
into O
liver O
mitochondria O
is O
at O
least O
partly O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex B
I I
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O
was O
weaker O
in O
octn1(-/-) O
mice O
than O
that O
in O
wild-type O
mice O
. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin O
into O
liver O
mitochondria O
is O
at O
least O
partly O
mediated O
by O
OCTN1 O
and O
functionally O
relevant O
to O
its O
inhibition O
potential O
of O
complex O
I O
respiration O
. O
This O
study O
was O
, O
thus O
, O
the O
first O
to O
demonstrate O
OCTN1-mediated O
mitochondrial O
transport O
and O
toxicity O
of O
biguanide O
in O
vivo O
in O
rodents O
. O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
complex B
I I
respiration O
in O
mitochondria.Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O
I O
inhibition O
by O
phenformin O
were O
examined O
in O
isolated O
liver O
and O
heart O
mitochondria O
. O
Uptake O
of O
phenformin O
into O
isolated O
rat O
liver O
mitochondria O
was O
higher O
than O
that O
into O
heart O
mitochondria O
. O
It O
was O
inhibited O
by O
several O
cat O
ionic O
compounds O
, O
which O
suggests O
the O
involvement O
of O
multispecific O
transport O
system(s) O
. O
Similar O
characteristics O
were O
also O
observed O
for O
uptake O
of O
TEA; O
however O
, O

phenformin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Role O
of O
organic B
cation/carnitine I
transporter I
1 I
in O
uptake O
of O
phenformi O
and O
inhibitory O
effect O
on O
complex O
I O
respiration O
in O
mitochondria.Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O

phenformin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex O
I O
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O
was O
weaker O
in O
octn1(-/-) O
mice O
than O
that O
in O
wild-type O
mice O
. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin O
into O
liver O
mitochondria O
is O
at O
least O
partly O
mediated O
by O
OCTN1 B
and O
functionally O
relevant O
to O
its O
inhibition O
potential O
of O
complex O
I O
respiration O
. O
This O
study O
was O
, O
thus O
, O
the O
first O
to O
demonstrate O
OCTN1-mediated O
mitochondrial O
transport O
and O
toxicity O
of O
biguanide O
in O
vivo O
in O
rodents O
. O

carbohydrate O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Results O
from O
the O
OmniHeart O
Trial.OBJECTIVE O
Impaired O
insulin B
sensitivity O
increases O
the O
risk O
of O
cardiovascular O
disease O
. O
Although O
calorie O
restriction O
and O
weight O
loss O
increase O
insulin O
sensitivity O
, O
the O
effects O
of O
modifying O
macronutrient O
composition O
on O
insulin O
sensitivity O
are O
uncertain O
. O
The O
purpose O
of O
this O
study O
is O
to O
determine O
the O
effects O
on O
insulin O
sensitivity O
of O
a O
carbohydrate O
rich O
diet O
(CARB; O
similar O
to O
the O
Dietary O
Approaches O
to O
Stop O
Hypertension O
[DASH] O
diet) O
, O
a O
protein-rich O
diet O
(PROT; O
protein O
predominantly O
from O
plant O
sources) O
, O
and O
an O
unsaturated O
fat-rich O
diet O
(UNSAT; O
predominantly O
monounsaturated) O
. O
RESEARCH O
DESIGN O
AND O
METHODS O
This O
study O
was O
a O
randomized O
, O
controlled O
, O
three-period O
, O
crossover O
feeding O
study O
. O
The O
study O
participants O
were O
164 O

Carbohydrate O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
Effects O
of O
Carbohydrat O
 O
, O
Unsaturated O
Fat O
, O
and O
Protein O
Intake O
on O
Measures O
of O
Insulin B
Sensitivity O
: O
Results O
from O
the O
OmniHeart O
Trial.OBJECTIVE O
Impaired O
insulin O
sensitivity O
increases O
the O
risk O
of O
cardiovascular O
disease O
. O
Although O
calorie O
restriction O
and O
weight O
loss O
increase O
insulin O
sensitivity O
, O
the O
effects O
of O
modifying O
macronutrient O
composition O
on O
insulin O
sensitivity O
are O
uncertain O
. O
The O
purpose O
of O
this O

carbohydrate O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
generalized O
estimating O
equations O
. O
RESULTS O
At O
baseline O
, O
mean O
(SD) O
BMI O
was O
30.2 O
(6.1) O
kg/m(2) O
, O
and O
mean O
(SD) O
QUICKI O
was O
0.35 O
(0.04) O
. O
The O
UNSAT O
diet O
increased O
QUICKI O
by O
0.005 O
, O
more O
than O
the O
CARB O
diet O
(P O
= O
0.04) O
. O
PROT O
had O
no O
significant O
effect O
compared O
with O
CARB O
. O
CONCLUSIONS O
A O
diet O
that O
partially O
replaces O
carbohydrate O
with O
unsaturated O
fat O
may O
improve O
insulin B
sensitivity O
in O
a O
population O
at O
risk O
for O
cardiovascular O
disease O
. O
Given O
the O
well-recognized O
challenges O
of O
sustaining O
weight O
loss O
, O
our O
results O
suggest O
an O
alternative O
approach O
for O
improving O
insulin O
sensitivity O
. O

cysteine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak B
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine O
166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 O
and O
suggests O
that O
Bak O
may O
be O

VK2 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O
Although O
its O
effect O
is O
thought O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
the O
induction O
of O
apoptosis O
, O
the O
underlying O
molecular O
mechanism O
remains O
elusive O
. O
Here O
, O
we O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak B
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O

VK2-2,3 O
epoxide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak B
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O

VK2 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
Bak B
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O

VK2 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak B
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 O
and O
suggests O
that O
Bak O
may O
be O
a O
potential O
target O
of O
cancer O
therapy O
. O

VK2 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(VK2 O
, O
menaquinone) O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O
Although O
its O
effect O
is O
thought O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
the O
induction O
of O
apoptosis O
, O
the O
underlying O
molecular O
mechanism O
remains O
elusive O
. O
Here O
, O
we O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2 O
induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak B
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O

VK2 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak O
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2 O
induced O
cytochrome B
c I
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O

VK2 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak O
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2 O
induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
that O
deletion O
of O
either O
subunit O
of O
the O
CBC O
confers O
a O
synthetic O
growth O
defect O
when O
combined O
with O
deletion O
of O
genes O
encoding O
either O
Ctk2 O
or O
Bur2 O
, O
a O
component O
of O
the O
Saccharomyces O
cerevisiae O
ortholog O
of O
P-TEFb O
. O
The O
CBC O
physically O
associates O
with O
these O
complexes O
to O
recruit O
them O
during O
transcription O
and O
mediates O
phosphorylation O
at O
Ser O
2 O
of O
the O
C-terminal O
domain O
(CTD) O
of O
RNA O
polymerase O
II O
. O
To O
understand O
how O
these O
interactions O
influence O
downstream O
events O
, O
histone O
H3K36me3 O
was O
examined O
, O
and O
we O
demonstrate O
that O
CBCΔ O
affects O
proper O
Set2-dependent O
H3K36me3 O
. O
Consistent O
with O
this O
, O
the O
CBC O
and O
Set2 O
have O
similar O
effects O
on O
the O
ability O
to O
rapidly O
induce O
and O
sustain O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
either O
subunit O
of O
the O
CBC O
confers O
a O
synthetic O
growth O
defect O
when O
combined O
with O
deletion O
of O
genes O
encoding O
either O
Ctk2 O
or O
Bur2 O
, O
a O
component O
of O
the O
Saccharomyces O
cerevisiae O
ortholog O
of O
P-TEFb O
. O
The O
CBC O
physically O
associates O
with O
these O
complexes O
to O
recruit O
them O
during O
transcription O
and O
mediates O
phosphorylation O
at O
Ser-2 O
of O
the O
C O
terminal O
domain O
(CTD) O
of O
RNA O
polymerase O
II O
. O
To O
understand O
how O
these O
interactions O
influence O
downstream O
events O
, O
histone O
H3K36me3 O
was O
examined O
, O
and O
we O
demonstrate O
that O
CBCΔ O
affects O
proper O
Set2-dependent O
H3K36me3 O
. O
Consistent O
with O
this O
, O
the O
CBC O
and O
Set2 O
have O
similar O
effects O
on O
the O
ability O
to O
rapidly O
induce O
and O
sustain O
activated O
gene O
expression O
, O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His O
157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys O
113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 B
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys O
113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
. O
The O
present O
study O
establishes O
that O

HNE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl B
cis/trans-isomerase I
A1 I
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O

HNE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O

8-alkynyl-HNE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O

HNE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
primary O
site O
of O
HNE O
modification O
. O
Pin1 B
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
. O
The O
present O
study O
establishes O
that O
it O
is O
also O
a O
target O
for O
electrophilic O
modification O

polyphenols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
MS O
data O
support O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 B
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
The O
present O
study O
establishes O
that O
it O
is O
also O
a O
target O
for O
electrophilic O
modification O
by O
products O
of O
lipid O
peroxidation O
. O

pSer O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
production O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl B
cis/trans-isomerase I
A1 I
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer O
pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O

pSer O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
production O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer O
pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O

pThr O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl B
cis/trans-isomerase I
A1 I
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer O
/ O
pThr O
Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O

pThr O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer O
/ O
pThr O
Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O

Pro O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl B
cis/trans-isomerase I
A1 I
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr- O
Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O

Pro O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr- O
Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
males O
has O
been O
largely O
neglected O
. O
Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen O
receptors O
α O
and O
β O
(ERα O
, O
β) O
in O
8-week-old O
, O
12-week-old O
and O
24-week-old O
male O
rats O
. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen O
receptor O
genes O
and O
other O
learning-related O
steroid O
receptors O
, O
androgen O
receptors O
(AR) O
, O
corticosterone O
binding O
glucocorticoid B
receptors I
(GR) O
and O
mineralocorticoid O
receptors O
(MR) O
were O
also O
measured O
. O
Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol O
, O
testosterone O
and O
corticosterone O
were O
measured O
. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board O
. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
males O
has O
been O
largely O
neglected O
. O
Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen O
receptors O
α O
and O
β O
(ERα O
, O
β) O
in O
8-week-old O
, O
12-week-old O
and O
24-week-old O
male O
rats O
. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen O
receptor O
genes O
and O
other O
learning-related O
steroid O
receptors O
, O
androgen O
receptors O
(AR) O
, O
corticosterone O
binding O
glucocorticoid O
receptors O
(GR) O
and O
mineralocorticoid O
receptors O
(MR) O
were O
also O
measured O
. O
Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol O
, O
testosterone O
and O
corticosterone O
were O
measured O
. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board O
. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
males O
has O
been O
largely O
neglected O
. O
Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen O
receptors O
α O
and O
β O
(ERα O
, O
β) O
in O
8-week-old O
, O
12-week-old O
and O
24-week-old O
male O
rats O
. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen O
receptor O
genes O
and O
other O
learning-related O
steroid O
receptors O
, O
androgen O
receptors O
(AR) O
, O
corticosterone O
binding O
glucocorticoid O
receptors O
(GR) O
and O
mineralocorticoid B
receptors I
(MR) O
were O
also O
measured O
. O
Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol O
, O
testosterone O
and O
corticosterone O
were O
measured O
. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board O
. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
males O
has O
been O
largely O
neglected O
. O
Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen O
receptors O
α O
and O
β O
(ERα O
, O
β) O
in O
8-week-old O
, O
12-week-old O
and O
24-week-old O
male O
rats O
. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen O
receptor O
genes O
and O
other O
learning-related O
steroid O
receptors O
, O
androgen O
receptors O
(AR) O
, O
corticosterone O
binding O
glucocorticoid O
receptors O
(GR) O
and O
mineralocorticoid O
receptors O
(MR) O
were O
also O
measured O
. O
Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol O
, O
testosterone O
and O
corticosterone O
were O
measured O
. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board O
. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
polymorphisms O
were O
associated O
with O
CYP2B6 B
activity O
. O
Evidence O
of O
dependence O
of O
CYP2B6 O
activity O
on O
ethnicity O
or O
genotype-by-ethnicity O
interactions O
was O
not O
detected O
in O
women O
. O
These O
results O
suggest O
that O
CYP2B6 O
genotype O
is O
the O
most O
important O
patient O
variable O
for O
predicting O
the O
level O
of O
CYP2B6 O
activity O
in O
women O
, O
when O
measured O
by O
the O
metabolism O
of O
bupropion O
The O
bupropion O
metabolic O
ratio O
appears O
to O
detect O
known O
differences O
in O
CYP2B6 O
activity O
associated O
with O
genetic O
polymorphism O
, O
across O
different O
ethnic O
groups O
. O
Prospective O
studies O
will O
be O
needed O
to O
validate O
the O
use O
of O
bupropion O
as O
a O
probe O
substrate O
for O
clinical O
use O
. O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
polymorphisms O
were O
associated O
with O
CYP2B6 B
activity O
. O
Evidence O
of O
dependence O
of O
CYP2B6 O
activity O
on O
ethnicity O
or O
genotype-by-ethnicity O
interactions O
was O
not O
detected O
in O
women O
. O
These O
results O
suggest O
that O
CYP2B6 O
genotype O
is O
the O
most O
important O
patient O
variable O
for O
predicting O
the O
level O
of O
CYP2B6 O
activity O
in O
women O
, O
when O
measured O
by O
the O
metabolism O
of O
bupropion O
The O
bupropion O
metabolic O
ratio O
appears O
to O
detect O
known O
differences O
in O
CYP2B6 O
activity O
associated O
with O
genetic O
polymorphism O
, O
across O
different O
ethnic O
groups O
. O
Prospective O
studies O
will O
be O
needed O
to O
validate O
the O
use O
of O
bupropion O
as O
a O
probe O
substrate O
for O
clinical O
use O
. O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
associated O
with O
CYP2B6 B
activity O
. O
Evidence O
of O
dependence O
of O
CYP2B6 O
activity O
on O
ethnicity O
or O
genotype-by-ethnicity O
interactions O
was O
not O
detected O
in O
women O
. O
These O
results O
suggest O
that O
CYP2B6 O
genotype O
is O
the O
most O
important O
patient O
variable O
for O
predicting O
the O
level O
of O
CYP2B6 O
activity O
in O
women O
, O
when O
measured O
by O
the O
metabolism O
of O
bupropion O
. O
The O
bupropion O
metabolic O
ratio O
appears O
to O
detect O
known O
differences O
in O
CYP2B6 O
activity O
associated O
with O
genetic O
polymorphism O
, O
across O
different O
ethnic O
groups O
. O
Prospective O
studies O
will O
be O
needed O
to O
validate O
the O
use O
of O
bupropion O
as O
a O
probe O
substrate O
for O
clinical O
use O
. O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
genetic O
polymorphism O
on O
hepatic O
CYP2B6 B
(cytochrome O
P450 O
2B6) O
expression O
and O
activity O
were O
previously O
demonstrated O
in O
vitro O
. O
Race/ethnic O
differences O
in O
CYP2B6 O
genotype O
and O
phenotype O
were O
observed O
only O
in O
women O
. O
To O
identify O
important O
covariates O
associated O
with O
interindividual O
variation O
in O
CYP2B6 O
activity O
in O
vivo O
, O
we O
evaluated O
these O
effects O
in O
healthy O
volunteers O
using O
bupropion O
(Wellbutrin O
SR O
GlaxoSmithKline O
, O
Research O
Triangle O
Park O
, O
NC) O
as O
a O
CYP2B6 O
probe O
substrate O
. O
A O
fixed O
150-mg O
oral O
sustained-release O
dose O
of O
bupropion O
was O
administered O
to O
100 O
healthy O
volunteers O
comprising O
four O
sex/ethnicity O
cohorts O
(n O
= O
25 O
each) O
: O
Caucasian O
men O
and O
Caucasian O
, O
African O
American O
, O
and O
Hispanic O
women O
. O
Blood O
samples O
were O
obtained O
at O
0 O

Wellbutrin O
SR O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
on O
hepatic O
CYP2B6 B
(cytochrome O
P450 O
2B6) O
expression O
and O
activity O
were O
previously O
demonstrated O
in O
vitro O
. O
Race/ethnic O
differences O
in O
CYP2B6 O
genotype O
and O
phenotype O
were O
observed O
only O
in O
women O
. O
To O
identify O
important O
covariates O
associated O
with O
interindividual O
variation O
in O
CYP2B6 O
activity O
in O
vivo O
, O
we O
evaluated O
these O
effects O
in O
healthy O
volunteers O
using O
bupropion O
( O
Wellbutrin O
SR O
GlaxoSmithKline O
, O
Research O
Triangle O
Park O
, O
NC) O
as O
a O
CYP2B6 O
probe O
substrate O
. O
A O
fixed O
150-mg O
oral O
sustained-release O
dose O
of O
bupropion O
was O
administered O
to O
100 O
healthy O
volunteers O
comprising O
four O
sex/ethnicity O
cohorts O
(n O
= O
25 O
each) O
: O
Caucasian O
men O
and O
Caucasian O
, O
African O
American O
, O
and O
Hispanic O
women O
. O
Blood O
samples O
were O
obtained O
at O
0 O
and O
6 O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
influence O
of O
sex O
, O
ethnicity O
, O
and O
CYP2B6 B
genotype O
on O
bupropio O
metabolism O
as O
an O
index O
of O
hepatic O
CYP2B6 O
activity O
in O
humans.The O
effects O
of O
sex O
, O
ethnicity O
, O
and O
genetic O
polymorphism O
on O
hepatic O
CYP2B6 O
(cytochrome O
P450 O
2B6) O
expression O
and O
activity O
were O
previously O
demonstrated O
in O
vitro O
. O
Race/ethnic O
differences O
in O
CYP2B6 O
genotype O
and O
phenotype O
were O
observed O
only O
in O
women O
. O
To O
identify O
important O
covariates O
associated O
with O

rifampicin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Within O
14 O
days O
of O
culture O
, O
the O
HepaRG-AMC-BALs O
contained O
highly O
polarized O
viable O
liver-like O
tissue O
with O
heterogeneous O
expression O
of O
CYP3A4 O
. O
We O
found O
a O
substantial O
metabolism O
of O
the O
tested O
substrates O
, O
ranging O
from O
26% O
(UDP-glucuronosyltransferase O
1A1) O
, O
47% O
(CYP3A4) O
, O
to O
240% O
(CYP2C9) O
of O
primary O
human O
hepatocytes O
. O
The O
CYP3A4 B
activity O
could O
be O
induced O
2-fold O
by O
rifampicin O
whereas O
CYP2C9 O
activity O
remained O
equally O
high O
. O
The O
HepaRG-AMC-BAL O
secreted O
bile O
acids O
at O
43% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation O
, O
conjugation O
, O
and O
transport O
of O
bile O
salts O
. O
Concluding O
, O
culturing O
HepaRG O
cells O
in O
the O
AMC-BAL O
yields O
substantial O
phase O
1 O
and O
phase O
2 O
drug O
metabolism O
, O
while O
maintaining O
high O
viability O
, O
rendering O

rifampicin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Within O
14 O
days O
of O
culture O
, O
the O
HepaRG-AMC-BALs O
contained O
highly O
polarized O
viable O
liver-like O
tissue O
with O
heterogeneous O
expression O
of O
CYP3A4 O
. O
We O
found O
a O
substantial O
metabolism O
of O
the O
tested O
substrates O
, O
ranging O
from O
26% O
(UDP-glucuronosyltransferase O
1A1) O
, O
47% O
(CYP3A4) O
, O
to O
240% O
(CYP2C9) O
of O
primary O
human O
hepatocytes O
. O
The O
CYP3A4 O
activity O
could O
be O
induced O
2-fold O
by O
rifampicin O
whereas O
CYP2C9 B
activity O
remained O
equally O
high O
. O
The O
HepaRG-AMC-BAL O
secreted O
bile O
acids O
at O
43% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation O
, O
conjugation O
, O
and O
transport O
of O
bile O
salts O
. O
Concluding O
, O
culturing O
HepaRG O
cells O
in O
the O
AMC-BAL O
yields O
substantial O
phase O
1 O
and O
phase O
2 O
drug O
metabolism O
, O
while O
maintaining O
high O
viability O
, O
rendering O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O
of O
Pb O
but O
exposure O
started O
on O
postnatal O
day O
1 O
and O
continued O
through O
weaning O
(early O
postnatal O
exposure O
group) O
. O
All O
animals O
were O
euthanized O
on O
day O
55 O
and O
hippocampi O
were O
removed O
. O
Western O
blot O
analyses O
showed O
significant O
effects O
of O
Pb O
exposure O
on O
DNMT1 O
, O
DNMT3a O
, O
and O
MeCP2 O
expression O
, O
with O
effects O
often O
seen O
at O
the O
lowest O
level O
of O
exposure O
and O
modified O
by O
sex O
and O
developmental O
window O
of O
Pb O
exposure O
. O
These O
data O
suggest O
potential O
epigenetic O
effects O
of O
developmental O
Pb O
exposure O
on O
DNA O
methylation O
mediated O
at O
least O
in O
part O
through O
dysregulation O
of O
methyltransferases O
. O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O
of O
Pb O
but O
exposure O
started O
on O
postnatal O
day O
1 O
and O
continued O
through O
weaning O
(early O
postnatal O
exposure O
group) O
. O
All O
animals O
were O
euthanized O
on O
day O
55 O
and O
hippocampi O
were O
removed O
. O
Western O
blot O
analyses O
showed O
significant O
effects O
of O
Pb O
exposure O
on O
DNMT1 O
, O
DNMT3a O
, O
and O
MeCP2 O
expression O
, O
with O
effects O
often O
seen O
at O
the O
lowest O
level O
of O
exposure O
and O
modified O
by O
sex O
and O
developmental O
window O
of O
Pb O
exposure O
. O
These O
data O
suggest O
potential O
epigenetic O
effects O
of O
developmental O
Pb O
exposure O
on O
DNA O
methylation O
mediated O
at O
least O
in O
part O
through O
dysregulation O
of O
methyltransferases O
. O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O
of O
Pb O
but O
exposure O
started O
on O
postnatal O
day O
1 O
and O
continued O
through O
weaning O
(early O
postnatal O
exposure O
group) O
. O
All O
animals O
were O
euthanized O
on O
day O
55 O
and O
hippocampi O
were O
removed O
. O
Western O
blot O
analyses O
showed O
significant O
effects O
of O
Pb O
exposure O
on O
DNMT1 O
, O
DNMT3a O
, O
and O
MeCP2 B
expression O
, O
with O
effects O
often O
seen O
at O
the O
lowest O
level O
of O
exposure O
and O
modified O
by O
sex O
and O
developmental O
window O
of O
Pb O
exposure O
. O
These O
data O
suggest O
potential O
epigenetic O
effects O
of O
developmental O
Pb O
exposure O
on O
DNA O
methylation O
mediated O
at O
least O
in O
part O
through O
dysregulation O
of O
methyltransferases O
. O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
adulthood O
. O
Exposures O
that O
occur O
during O
fetal O
or O
early O
life O
periods O
may O
produce O
changes O
in O
brain O
related O
to O
physiological O
re-programming O
from O
an O
epigenetic O
influence O
such O
as O
altered O
DNA O
methylation O
status O
. O
Since O
DNA O
methylation O
is O
regulated O
by O
DNA B
methyltransferases I
and O
methyl O
cytosine-binding O
proteins O
, O
this O
study O
assessed O
the O
extent O
to O
which O
developmental O
Pb O
exposure O
might O
affect O
expression O
of O
these O
proteins O
in O
the O
hippocampus O
. O
Long O
Evans O
dams O
were O
fed O
chow O
with O
or O
without O
added O
Pb O
acetate O
(0 O
, O
150 O
, O
375 O
, O
750 O
ppm) O
prior O
to O
breeding O
and O
remained O
on O
the O
same O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
adulthood O
. O
Exposures O
that O
occur O
during O
fetal O
or O
early O
life O
periods O
may O
produce O
changes O
in O
brain O
related O
to O
physiological O
re-programming O
from O
an O
epigenetic O
influence O
such O
as O
altered O
DNA O
methylation O
status O
. O
Since O
DNA O
methylation O
is O
regulated O
by O
DNA O
methyltransferases O
and O
methyl O
cytosine-binding O
proteins O
, O
this O
study O
assessed O
the O
extent O
to O
which O
developmental O
Pb O
exposure O
might O
affect O
expression O
of O
these O
proteins O
in O
the O
hippocampus O
. O
Long O
Evans O
dams O
were O
fed O
chow O
with O
or O
without O
added O
Pb O
acetate O
(0 O
, O
150 O
, O
375 O
, O
750 O
ppm) O
prior O
to O
breeding O
and O
remained O
on O
the O
same O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 B
and O
ALDH1B1 O
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O
many O
mammalian O
species O
and O
in O
frogs O
(Xenopus O
tropicalis); O
no O
evidence O
was O
found O
for O
ALDH1B1 O
in O
the O
genomes O
of O
birds O
, O
reptiles O
or O
fish O
. O
Predicted O
vertebrate O
ALDH2 O
and O
ALDH1B1 O
subunit O
sequences O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 B
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O
many O
mammalian O
species O
and O
in O
frogs O
(Xenopus O
tropicalis); O
no O
evidence O
was O
found O
for O
ALDH1B1 O
in O
the O
genomes O
of O
birds O
, O
reptiles O
or O
fish O
. O
Predicted O
vertebrate O
ALDH2 O
and O
ALDH1B1 O
subunit O
sequences O

acetaldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Comparative O
genomics O
, O
molecular O
evolution O
and O
computational O
modeling O
of O
ALDH1B1 O
and O
ALDH2.Vertebrate O
ALDH2 O
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde O
and O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 O
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O

acetaldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Comparative O
genomics O
, O
molecular O
evolution O
and O
computational O
modeling O
of O
ALDH1B1 O
and O
ALDH2.Vertebrate O
ALDH2 B
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde O
and O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 O
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O

BGG O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG O
mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK B
and O
p38 O
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O
associated O
with O
chronic O
inflammation O
. O
In O
this O
study O
, O
we O
also O
demonstrated O
that O
treatment O
with O
BGG O
decreased O
the O
number O
of O
inflammatory O
cells O
that O
infiltrate O

BGG O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG O
mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK O
and O
p38 B
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O
associated O
with O
chronic O
inflammation O
. O
In O
this O
study O
, O
we O
also O
demonstrated O
that O
treatment O
with O
BGG O
decreased O
the O
number O
of O
inflammatory O
cells O
that O
infiltrate O

Beta-glucogallin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG-mediated O
inhibition O
of O
AR O

BGG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
( O
BGG O
 O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG-mediated O
inhibition O
of O
AR O

BGG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG-mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK O
and O
p38 O
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O

BGG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG O
mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK O
and O
p38 O
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O
associated O
with O
chronic O
inflammation O
. O
In O
this O
study O
, O
we O
also O
demonstrated O
that O
treatment O
with O
BGG O
decreased O
the O
number O
of O
inflammatory O
cells O
that O
infiltrate O

alcohol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O

alcohol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O

aldehydes O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O

aldehydes O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O

valine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
distribution O
of O
the O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafenib O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF B
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O
Clinical O
trials O
with O
dabrafenib O
have O
shown O
encouraging O
results; O
however O
, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib O
remains O
unknown O
. O
Thus O
, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O

glutamic O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafenib O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF B
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O
Clinical O
trials O
with O
dabrafenib O
have O
shown O
encouraging O
results; O
however O
, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib O
remains O
unknown O
. O
Thus O
, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O

dabrafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafeni O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF O
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O

dabrafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafeni O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF O
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O

vemurafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
0.023 O
, O
which O
increased O
by O
18-fold O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
to O
0.42 O
. O
Dabrafenib O
plasma O
exposure O
was O
∼2-fold O
greater O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
as O
compared O
with O
wild-type O
with O
an O
oral O
dose O
(25 O
mg/kg); O
however O
, O
the O
brain O
distribution O
was O
increased O
by O
~10-fold O
with O
a O
resulting O
K(p) O
of O
0.25 O
. O
Further O
, O
compared O
with O
vemurafenib O
another O
BRAF(V600E) O
inhibitor O
, O
dabrafenib O
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O
In O
conclusion O
, O
the O
dabrafenib O
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model O
, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases O
. O

vemurafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
0.023 O
, O
which O
increased O
by O
18-fold O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
to O
0.42 O
. O
Dabrafenib O
plasma O
exposure O
was O
∼2-fold O
greater O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
as O
compared O
with O
wild-type O
with O
an O
oral O
dose O
(25 O
mg/kg); O
however O
, O
the O
brain O
distribution O
was O
increased O
by O
~10-fold O
with O
a O
resulting O
K(p) O
of O
0.25 O
. O
Further O
, O
compared O
with O
vemurafenib O
another O
BRAF(V600E) O
inhibitor O
, O
dabrafenib O
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O
In O
conclusion O
, O
the O
dabrafenib O
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model O
, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases O
. O

dabrafenib O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O
efflux O
by O
P-glycoprotein O
(P-gp) O
and O
breast O
cancer O
resistance O
protein O
(BCRP) O
restricts O
its O
delivery O
across O
the O
blood-brain O
barrier O
(BBB) O
. O
In O
vitro O
accumulation O
studies O
conducted O
in O
Madin-Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib O
is O
an O
avid O
substrate O
for O
both O
P-gp B
and O
BCRP O
. O
Directional O
flux O
studies O
revealed O
greater O
transport O
in O
the O
basolateral O
to O
apical O
direction O
with O
corrected O
efflux O
ratios O
greater O
than O
2 O
for O
both O
P-gp O
and O
Bcrp1 O
transfected O
cell O
lines O
. O
In O
vivo O
, O
the O
ratio O
of O
area O
under O
the O
concentration-time O
curve O
(AUC)(brain) O
to O
AUC(plasma) O

dabrafenib O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O
efflux O
by O
P-glycoprotein O
(P-gp) O
and O
breast O
cancer O
resistance O
protein O
(BCRP) O
restricts O
its O
delivery O
across O
the O
blood-brain O
barrier O
(BBB) O
. O
In O
vitro O
accumulation O
studies O
conducted O
in O
Madin-Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib O
is O
an O
avid O
substrate O
for O
both O
P-gp O
and O
BCRP O
. O
Directional O
flux O
studies O
revealed O
greater O
transport O
in O
the O
basolateral O
to O
apical O
direction O
with O
corrected O
efflux O
ratios O
greater O
than O
2 O
for O
both O
P-gp O
and O
Bcrp1 O
transfected O
cell O
lines O
. O
In O
vivo O
, O
the O
ratio O
of O
area O
under O
the O
concentration-time O
curve O
(AUC)(brain) O
to O
AUC(plasma) O

sulfate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
that O
the O
intrinsic O
PK/PD O
properties O
of O
native O
FST315 O
are O
poorly O
suited O
for O
acting O
as O
a O
parentally O
administered O
biotherapeutic O
with O
broad O
systemic O
effects O
. O
Here O
, O
we O
leveraged O
protein O
engineering O
to O
modify O
the O
PK O
characteristics O
of O
the O
native O
molecule O
by O
fusing O
FST315 O
to O
a O
murine O
IgG(1) O
Fc O
and O
removing O
the O
intrinsic O
heparan O
sulfate O
binding O
activity O
of O
follistatin O
. O
The O
engineered O
variant O
molecule O
had O
~100- O
and O
~1600-fold O
improvements O
in O
terminal O
half-life O
and O
exposure O
, O
respectively O
. O
In O
contrast O
to O
the O
native O
FST315 O
, O
the O
variant O
showed O
a O
robust O
, O
dose-dependent O
pharmacological O
effect O
when O
administered O
subcutaneously O
on O
a O
weekly O
basis O
in O
mouse O
models O
of O
muscle O
atrophy O
and O
degeneration O
. O
These O

2'-O-methyl O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
from O
crude O
cell O
lysates.Small O
interfering O
RNAs O
(siRNAs) O
direct O
Argonaute O
proteins O
, O
the O
core O
components O
of O
the O
RNA-induced O
silencing O
complex O
(RISC) O
, O
to O
cleave O
complementary O
target O
RNAs O
. O
Here O
, O
we O
describe O
a O
method O
to O
purify O
active O
RISC B
containing O
a O
single O
, O
unique O
small O
RNA O
guide O
sequence O
. O
We O
begin O
by O
capturing O
RISC O
using O
a O
complementary O
2'-O-methyl O
oligonucleotide O
tethered O
to O
beads O
. O
Unlike O
other O
methods O
that O
capture O
RISC O
but O
do O
not O
allow O
its O
recovery O
, O
our O
strategy O
purifies O
active O
, O
soluble O
RISC O
in O
good O
yield O
. O
The O
method O
takes O
advantage O
of O
the O
finding O
that O
RISC O
partially O
paired O
to O
a O
target O
through O
its O
siRNA O
guide O
dissociates O
more O
than O
300 O
times O
faster O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 B
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB B
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 B
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 B
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB B
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 B
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 B
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 B
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 B
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin O
treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin O
treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
p65 O
protein O
, O
and O
IL-27 B
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin O
treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

sulfasalazine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 B
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine O
treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

sulfasalazine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine O
treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

sulfasalazine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
IL-27 B
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine O
treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 B
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase B
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

(129)I O
acts O
as O
PART-OF O
for O
what O
entity O
? O
pharmacologic O
effect O
. O
In O
microdosing O
, O
use O
is O
made O
of O
accelerator O
MS O
(AMS) O
. O
In O
this O
study O
, O
we O
investigated O
whether O
(129)I-labeling O
of O
proteins O
with O
subsequent O
AMS O
measurements O
is O
a O
suitable O
method O
to O
perform O
microdose O
studies O
with O
therapeutic O
proteins O
. O
We O
used O
erythropoietin O
(EPO) O
as O
a O
case O
study O
. O
RESULTS O
: O
In O
an O
animal O
study O
with O
(129)I O
labeled O
EPO B
in O
Han-Wistar O
rats O
, O
an O
increase O
of O
(129)I-EPO O
is O
observed O
after O
dose O
administration O
. O
The O
half-life O
was O
found O
to O
be O
2 O
and O
5.5 O
h O
for O
two O
different O
EPOs O
. O
These O
results O
are O
in O
accordance O
with O
expected O
values O
. O
CoNCLUSION O
: O
Although O
further O
research O
is O
required O
, O
(129)I-labeling O
of O
proteins O
seems O
a O
feasible O
method O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
effects O
of O
kisspeptin O
in O
human O
reproductive O
function O
- O
therapeutic O
implications.Kisspeptin O
is O
a O
54- O
amino O
acid O
peptide O
which O
is O
encoded O
by O
the O
KiSS-1 O
gene O
and O
activates O
the O
G O
protein-coupled O
receptor O
GPR54 O
. O
Evidence O
suggests O
that O
this O
system O
is O
a O
key O
regulator O
of O
mammalian O
and O
human O
reproduction O
. O
Animal O
studies O
have O
shown O
that O
GPR54-deficient O
mice O
have O
abnormal O
sexual O
development O
. O
Central O
and O
peripheral O
administration O
of O
kisspeptin O
stimulates O
the O
hypothalamic-pituitary-gonadal O

gonadotrophin O
releasing O
hormone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
gene O
and O
activates O
the O
G O
protein-coupled O
receptor O
GPR54 O
. O
Evidence O
suggests O
that O
this O
system O
is O
a O
key O
regulator O
of O
mammalian O
and O
human O
reproduction O
. O
Animal O
studies O
have O
shown O
that O
GPR54-deficient O
mice O
have O
abnormal O
sexual O
development O
. O
Central O
and O
peripheral O
administration O
of O
kisspeptin B
stimulates O
the O
hypothalamic-pituitary-gonadal O
(HPG) O
axis O
whilst O
pre-administration O
of O
a O
gonadotrophin O
releasing O
hormone O
(GnRH) O
antagonist O
abolishes O
this O
effect O
. O
In O
humans O
, O
inactivating O
GPR54 O
mutations O
cause O
normosmic O
hypogonadotrophic O
hypogonadism O
whilst O
activation O
of O
GPR54 O
signalling O
is O
associated O
with O
premature O
puberty O
. O
In O
healthy O
human O
volunteers O
, O
the O
acute O
intravenous O
administration O
of O
kisspeptin O
potently O
increases O
plasma O
luteinising O
hormone O
(LH) O
levels O
and O
significantly O
increases O
plasma O
follicle O
stimulating O
hormone O

GnRH O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
G O
protein-coupled O
receptor O
GPR54 O
. O
Evidence O
suggests O
that O
this O
system O
is O
a O
key O
regulator O
of O
mammalian O
and O
human O
reproduction O
. O
Animal O
studies O
have O
shown O
that O
GPR54-deficient O
mice O
have O
abnormal O
sexual O
development O
. O
Central O
and O
peripheral O
administration O
of O
kisspeptin B
stimulates O
the O
hypothalamic-pituitary-gonadal O
(HPG) O
axis O
whilst O
pre-administration O
of O
a O
gonadotrophin O
releasing O
hormone O
( O
GnRH O
antagonist O
abolishes O
this O
effect O
. O
In O
humans O
, O
inactivating O
GPR54 O
mutations O
cause O
normosmic O
hypogonadotrophic O
hypogonadism O
whilst O
activation O
of O
GPR54 O
signalling O
is O
associated O
with O
premature O
puberty O
. O
In O
healthy O
human O
volunteers O
, O
the O
acute O
intravenous O
administration O
of O
kisspeptin O
potently O
increases O
plasma O
luteinising O
hormone O
(LH) O
levels O
and O
significantly O
increases O
plasma O
follicle O
stimulating O
hormone O
(FSH) O
and O

darapladib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
tailored O
activity O
probes O
for O
lipoprotein-associated O
phospholipase O
A(2).Lipoprotein-associated O
phospholipase O
A(2) O
(Lp-PLA(2) O
or O
PLA(2)G7) O
binds O
to O
low-density O
lipoprotein O
(LDL) O
particles O
, O
where O
it O
is O
thought O
to O
hydrolyze O
oxidatively O
truncated O
phospholipids O
. O
Lp-PLA(2) B
has O
also O
been O
implicated O
as O
a O
pro-tumorigenic O
enzyme O
in O
human O
prostate O
cancer O
. O
Several O
inhibitors O
of O
Lp-PLA(2) O
have O
been O
described O
, O
including O
darapladib O
which O
is O
currently O
in O
phase O
3 O
clinical O
development O
for O
the O
treatment O
of O
atherosclerosis O
. O
The O
selectivity O
that O
darapladib O
and O
other O
Lp-PLA(2) O
inhibitors O
display O
across O
the O
larger O
serine O
hydrolase O
family O
has O
not O
, O
however O
, O
been O
reported O
. O
Here O
, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) O
and O

darapladib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
atherosclerosis O
. O
The O
selectivity O
that O
darapladib O
and O
other O
Lp-PLA(2) B
inhibitors O
display O
across O
the O
larger O
serine O
hydrolase O
family O
has O
not O
, O
however O
, O
been O
reported O
. O
Here O
, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) O
and O
inhibitors O
of O
this O
enzyme O
in O
native O
biological O
systems O
. O
We O
show O
that O
both O
darapladib O
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate O
inhibitors O
inactivate O
Lp-PLA(2) O
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity O
. O
Our O
findings O
thus O
identify O
both O
inhibitors O
and O
chemoproteomic O
probes O
that O
are O
suitable O
for O
investigating O
Lp-PLA(2) O
function O
in O
biological O
systems O
. O

carbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitors O
display O
across O
the O
larger O
serine O
hydrolase O
family O
has O
not O
, O
however O
, O
been O
reported O
. O
Here O
, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) B
and O
inhibitors O
of O
this O
enzyme O
in O
native O
biological O
systems O
. O
We O
show O
that O
both O
darapladib O
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate O
inhibitors O
inactivate O
Lp-PLA(2) O
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity O
. O
Our O
findings O
thus O
identify O
both O
inhibitors O
and O
chemoproteomic O
probes O
that O
are O
suitable O
for O
investigating O
Lp-PLA(2) O
function O
in O
biological O
systems O
. O

benzofuran O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Identification O
of O
benzofura O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O

benzofurans O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H B
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O
engagement O
and O
provides O
a O
useful O
tool O
to O
explore O
a O
LTA(4)H O
inhibitor O
for O
the O
treatment O
of O
inflammatory O

Benzofuran O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O
engagement O
and O
provides O
a O
useful O
tool O
to O
explore O
a O
LTA(4)H B
inhibitor O
for O
the O
treatment O
of O
inflammatory O
diseases O
, O
such O
as O
asthma O
and O
inflammatory O
bowel O
disease O
(IBD) O
. O

LTB(4) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O

LTB(4) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene B
A(4) I
hydrolase I
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O

LTA(4) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O

LTA(4) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene B
A(4) I
hydrolase I
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour B
necrosis I
factor-α I
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β B
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β B
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 B
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear B
factor-κB I
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 B
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 B
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated B
protein I
kinase I
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis B
signal-regulating I
kinase I
1 I
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
from O
inflammation-mediated O
toxicity.A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β B
1-42 I
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
from O
inflammation-mediated O
toxicity.A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O

indole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β B
1-42 I
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O

indole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O

Neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O

Jaspamide O
acts O
as O
NOT O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 B
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

Jaspamide O
acts O
as O
NOT O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

jaspamide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
jaspamid O
on O
human O
cardiomyocyte O
function O
and O
cardiac B
ion I
channel I
activity.Jaspamide O
(jasplakinolide; O
NSC-613009) O
is O
a O
cyclodepsipeptide O
that O
has O
antitumor O
activity O
. O
A O
narrow O
margin O
of O
safety O
was O
observed O
between O
doses O
required O
for O
efficacy O
in O
mouse O
tumor O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O

Jaspamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

Jaspamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

Jaspamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

trans-dihydromorin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
Cudrania O
tricuspidata O
were O
found O
to O
show O
strong O
tyrosinase B
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol O
glucoside O
, O
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside O
(1) O
, O
plus O
twenty-seven O
known O
compounds O
(2-28) O
. O
Their O
structures O
were O
elucidated O
on O
the O
basis O
of O
ESI-MS O
and O
NMR O
spectral O
data O
. O
Among O
the O
isolated O
compounds O
, O
trans-dihydromorin O
(8) O
, O
oxyresveratrol O
(9) O
, O
and O
steppogenin O
(12) O
were O
found O
to O
exhibit O
significant O
tyrosinase O
inhibition O
activities O
. O
Moreover O
, O
the O
structure-activity O
relationship O
of O
these O
isolated O
compounds O
was O
also O
discussed O
. O

oxyresveratrol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
tricuspidata O
were O
found O
to O
show O
strong O
tyrosinase B
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol O
glucoside O
, O
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside O
(1) O
, O
plus O
twenty-seven O
known O
compounds O
(2-28) O
. O
Their O
structures O
were O
elucidated O
on O
the O
basis O
of O
ESI-MS O
and O
NMR O
spectral O
data O
. O
Among O
the O
isolated O
compounds O
, O
trans-dihydromorin O
(8) O
, O
oxyresveratrol O
(9) O
, O
and O
steppogenin O
(12) O
were O
found O
to O
exhibit O
significant O
tyrosinase O
inhibition O
activities O
. O
Moreover O
, O
the O
structure-activity O
relationship O
of O
these O
isolated O
compounds O
was O
also O
discussed O
. O

steppogenin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
show O
strong O
tyrosinase B
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol O
glucoside O
, O
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside O
(1) O
, O
plus O
twenty-seven O
known O
compounds O
(2-28) O
. O
Their O
structures O
were O
elucidated O
on O
the O
basis O
of O
ESI-MS O
and O
NMR O
spectral O
data O
. O
Among O
the O
isolated O
compounds O
, O
trans-dihydromorin O
(8) O
, O
oxyresveratrol O
(9) O
, O
and O
steppogenin O
(12) O
were O
found O
to O
exhibit O
significant O
tyrosinase O
inhibition O
activities O
. O
Moreover O
, O
the O
structure-activity O
relationship O
of O
these O
isolated O
compounds O
was O
also O
discussed O
. O

Cortisol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 B
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 O
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O
many O
conceptus O
elongation-related O
genes O
in O
the O
endometrium O
. O
Some O
effects O
of O
cortisol O
and O
IFNT O
were O
mediated O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O

Cortisol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 O
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 B
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O
many O
conceptus O
elongation-related O
genes O
in O
the O
endometrium O
. O
Some O
effects O
of O
cortisol O
and O
IFNT O
were O
mediated O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O

Cortisol O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 B
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 O
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O
many O
conceptus O
elongation-related O
genes O
in O
the O
endometrium O
. O
Some O
effects O
of O
cortisol O
and O
IFNT O
were O
mediated O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O

PF O
915275 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O
has O
a O
biological O
role O
in O
endometrial O
function O
and O
conceptus O
development O
during O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 B
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 O
activity O
and O

meloxicam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O
has O
a O
biological O
role O
in O
endometrial O
function O
and O
conceptus O
development O
during O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 O
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 B
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 B
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O
has O
a O
biological O
role O
in O
endometrial O
function O
and O
conceptus O
development O
during O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O

prostaglandins O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG B
synthase I
2 I
(PTGS2) O
and O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 O
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O

prostaglandins O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG O
synthase O
2 O
(PTGS2) O
and O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 O
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O
or O
recombinant O
ovine O
IFNT O
and O
into O
the O
uterus O
from O
day O
10 O
to O
day O
14 O
after O
mating O
. O
Inhibition O
of O
HSD11B1 B
activity O
in O
utero O
prevented O
conceptus O
elongation O
, O
whereas O
IFNT O
rescued O
conceptus O
elongation O
in O
PF-infused O
ewes O
. O
These O
results O
suggest O
that O
HSD11B1-derived O
cortisol O
mediates O
, O
in O
part O
, O
actions O
of O
ovarian O
progesterone O
and O
the O
conceptus O
on O
endometrial O
function O
and O
support O
the O
hypothesis O
that O
IFNT O
, O
PG O
, O
and O
cortisol O
coordinately O
regulate O
endometrial O
functions O
important O
for O
conceptus O
elongation O
and O
implantation O
during O
early O
pregnancy O
in O
sheep O
. O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG O
synthase O
2 O
(PTGS2) O
and O
cortisol O
via O
hydroxysteroid B
(11-β) I
dehydrogenase I
1 I
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 O
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG O
synthase O
2 O
(PTGS2) O
and O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 B
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O

isoflavone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
biological O
activities O
of O
an O
alcohol O
extract O
of O
groundnut O
containing O
genistein-7-O-gentiobioside O
as O
the O
main O
component O
. O
Although O
the O
groundnut O
extract O
by O
itself O
did O
not O
show O
antioxidative O
activity O
, O
it O
drove O
the O
antioxidative O
system O
in O
cells O
. O
Pretreatment O
of O
human O
breast O
carcinoma O
MCF-7 O
cells O
for O
24 O
h O
with O
the O
groundnut O
extract O
and O
soybean O
isoflavone O
increased O
gene O
expression O
of O
heme B
oxygenase-1 I
(HO-1) O
, O
a O
major O
antioxidative O
stress O
enzyme O
. O
These O
groundnut O
extract-treated O
cells O
showed O
antioxidative O
activity O
against O
free O
radicals O
derived O
from O
a O
radical O
initiator O
. O
Pretreatment O
of O
cells O
with O
100 O
μg/mL O
groundnut O
extract O
prevented O
the O
depletion O
of O
glutathione O
by O
the O
radical O
initiator; O
however O
, O
treatment O
with O
100 O
μg/mL O

isoflavone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
biological O
activities O
of O
an O
alcohol O
extract O
of O
groundnut O
containing O
genistein-7-O-gentiobioside O
as O
the O
main O
component O
. O
Although O
the O
groundnut O
extract O
by O
itself O
did O
not O
show O
antioxidative O
activity O
, O
it O
drove O
the O
antioxidative O
system O
in O
cells O
. O
Pretreatment O
of O
human O
breast O
carcinoma O
MCF-7 O
cells O
for O
24 O
h O
with O
the O
groundnut O
extract O
and O
soybean O
isoflavone O
increased O
gene O
expression O
of O
heme O
oxygenase-1 O
(HO-1) O
, O
a O
major O
antioxidative O
stress O
enzyme O
. O
These O
groundnut O
extract-treated O
cells O
showed O
antioxidative O
activity O
against O
free O
radicals O
derived O
from O
a O
radical O
initiator O
. O
Pretreatment O
of O
cells O
with O
100 O
μg/mL O
groundnut O
extract O
prevented O
the O
depletion O
of O
glutathione O
by O
the O
radical O
initiator; O
however O
, O
treatment O
with O
100 O
μg/mL O

acyl O
esters O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O
of O
alcohol B
acyl-transferase I
EEB1 I
and O
the O
acyl O
esterase O
IAH1 O
. O

acyl O
esters O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O
of O
alcohol O
acyl-transferase O
EEB1 O
and O
the O
acyl O
esterase O
IAH1 O
. O

ammonium O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
alcohol/ester O
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cachaça O
fermentation O
. O
Sugar-cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen O
(81 O
mg O
N/L) O
, O
was O
further O
supplemented O
with O
mid-range O
or O
high O
concentrations O
of O
ammonium O
sulfate O
. O
Overall O
, O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O

ammonium O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
alcohol/ester O
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cachaça O
fermentation O
. O
Sugar-cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen O
(81 O
mg O
N/L) O
, O
was O
further O
supplemented O
with O
mid-range O
or O
high O
concentrations O
of O
ammonium O
sulfate O
. O
Overall O
, O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases B
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O

ammonium O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
alcohol/ester O
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cachaça O
fermentation O
. O
Sugar-cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen O
(81 O
mg O
N/L) O
, O
was O
further O
supplemented O
with O
mid-range O
or O
high O
concentrations O
of O
ammonium O
sulfate O
. O
Overall O
, O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases B
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O

SCH O
900229 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure O
activity O
relationship O
studies O
of O
tricyclic O
bispyran O
sulfone O
γ-secretase O
inhibitors.An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone O
side O
chains O
of O
compound O
(-)-1a O
( O
SCH O
900229 O
 O
, O
a O
potent O
, O
PS1-selective O
γ-secretase O
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease O
. O
Specifically O
, O
4-CF(3) O
and O
4-Br O
substituted O
arylsulfone O
analogs O
, O
(-)-1b O
and O
(-)-1c O
, O
are O
equipotent O
to O
compound O
(-)-1a O
. O
On O
the O
right O
hand O
side O
chain O
, O
linker O
size O
and O
terminal O
substituents O
of O
the O
pendant O
sulfone O
group O
are O
also O
investigated O
. O

SCH O
900229 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure O
activity O
relationship O
studies O
of O
tricyclic O
bispyran O
sulfone O
γ-secretase B
inhibitors.An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone O
side O
chains O
of O
compound O
(-)-1a O
( O
SCH O
900229 O
 O
, O
a O
potent O
, O
PS1-selective O
γ-secretase O
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease O
. O
Specifically O
, O
4-CF(3) O
and O
4-Br O
substituted O
arylsulfone O
analogs O
, O
(-)-1b O
and O
(-)-1c O
, O
are O
equipotent O
to O
compound O
(-)-1a O
. O
On O
the O
right O
hand O
side O
chain O
, O
linker O
size O
and O
terminal O
substituents O
of O
the O
pendant O
sulfone O
group O
are O
also O
investigated O
. O

tricyclic O
bispyran O
sulfone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure O
activity O
relationship O
studies O
of O
tricyclic O
bispyran O
sulfon O
γ-secretase B
inhibitors.An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone O
side O
chains O
of O
compound O
(-)-1a O
(SCH O
900229) O
, O
a O
potent O
, O
PS1-selective O
γ-secretase O
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease O
. O
Specifically O
, O
4-CF(3) O
and O
4-Br O
substituted O
arylsulfone O
analogs O
, O
(-)-1b O
and O
(-)-1c O
, O
are O
equipotent O
to O

calpeptin O
acts O
as O
NOT O
for O
what O
entity O
? O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF B
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

ALD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 B
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O

ALD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 B
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain B
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
( O
ALD O
-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain B
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O

aldosterone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain B
and O
apoptosis-inducing O
factor O
in O
aldosteron O
-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O

aldosterone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing B
factor I
in O
aldosteron O
-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain B
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid B
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD O
induced O
increase O
of O
calpain B
and O
AIF O
levels O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF B
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD O
induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

aldosterone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain B
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O

EGTA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(tBid) O
, O
calpain B
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O

EGTA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid B
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O

EGTA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF B
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

spironoclactone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain B
and O
AIF O
levels O
. O

spironoclactone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF B
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

EGTA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 B
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O

SFO O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO O
HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O
The O
effects O
of O
SFO O
in O
mammalian O
systems O
, O
especially O
the O
cardiovascular O
system O
, O
are O
little O
known O
. O
Disruption O
of O
vulnerable O
atherosclerotic O
plaques O
in O
atherosclerosis O
, O
a O
chronic O
inflammatory O
disease O
, O
is O
the O
main O
cause O
of O
cardiovascular O
events O
. O
In O
this O
study O
, O
we O
investigated O
SFO O
induced O
atherosclerotic O
plaque O
vulnerability O
(possibility O
of O
rupture) O
in O
apolipoprotein O
E-knockout O
(apoE(-/-)) O
mice O
. O
Lipid O
area O
in O
vessel O
wall O
reached O
59.8% O
in O
high O
dose O
SFO O
(SFO-HD) O
treated O
group O
, O
which O
is O
only O
31.2% O
in O
control O
group O
. O
SFO O
treatment O
changed O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O

SFO O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O
The O
effects O
of O
SFO O
in O
mammalian O
systems O
, O
especially O
the O
cardiovascular O
system O
, O
are O
little O
known O
. O
Disruption O
of O
vulnerable O
atherosclerotic O
plaques O
in O
atherosclerosis O
, O
a O
chronic O
inflammatory O
disease O
, O
is O
the O
main O
cause O
of O
cardiovascular O
events O
. O
In O
this O
study O
, O
we O
investigated O
SFO O
induced O
atherosclerotic O
plaque O
vulnerability O
(possibility O
of O
rupture) O
in O
apolipoprotein O
E-knockout O
(apoE(-/-)) O
mice O
. O
Lipid O
area O
in O
vessel O
wall O
reached O
59.8% O
in O
high O
dose O
SFO O
(SFO-HD) O
treated O
group O
, O
which O
is O
only O
31.2% O
in O
control O
group O
. O
SFO O
treatment O
changed O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O

SFO O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
endothelium O
level O
of O
p75(NTR) B
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 B
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O
in O
plaque O
and O
the O
endothelium O
in O
plaques O
was O
damaged O
after O
SFO O
treatment O
. O
Furthermore O
, O
compared O
with O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) B
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO O
HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O

SFO O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O
in O
plaque O
and O
the O
endothelium O
in O
plaques O
was O
damaged O
after O
SFO O
treatment O
. O
Furthermore O
, O
compared O
with O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) B
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO O
HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O

SFO O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 B
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO O
HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha B
chemokine I
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO O
HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

rifampicin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
acetylcholinesterase O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O
that O
compounds O
moderately O
inhibit O
both O
acetylcholinesterase O
and O
butyrylcholinesterase O
. O
β-Amyloid O
aggregation O
results O
showed O
that O
all O
compounds O
exhibited O
remarkable O
Aβ B
fibril O
aggregation O
inhibition O
activity O
with O
a O
nearly O
similar O
potential O
as O
the O
reference O
compound O
rifampicin O
which O
makes O
them O
promising O
anti-Alzheimer O
drug O
candidates O
. O
Docking O
experiments O
were O
carried O
out O
with O
the O
aim O
to O
understand O
the O
interactions O
of O
the O
most O
active O
compounds O
with O
the O
active O
site O
of O
the O
cholinesterase O
enzymes O
. O

N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
Aβ O
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O
that O
compounds O
moderately O
inhibit O
both O
acetylcholinesterase B
and O
butyrylcholinesterase O
. O
β-Amyloid O
aggregation O
results O
showed O
that O
all O
compounds O
exhibited O
remarkable O
Aβ O
fibril O
aggregation O
inhibition O

N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
Aβ O
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesterase B
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O
that O
compounds O
moderately O
inhibit O
both O
acetylcholinesterase O
and O
butyrylcholinesterase O
. O
β-Amyloid O
aggregation O
results O
showed O
that O
all O
compounds O
exhibited O
remarkable O
Aβ O
fibril O
aggregation O
inhibition O

N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazon O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases B
and O
Aβ O
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O

N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazon O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
Aβ B
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O

Doxorubicin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
NF-κB-associated O
mechanisms O
underlying O
the O
response O
of O
embryonic O
cells O
to O
Doxorubici O
.The O
involvement O
of O
NF-κB B
in O
the O
regulation O
of O
teratogen-induced O
apoptosis O
has O
not O
been O
established O
yet O
. O
Therefore O
, O
we O
tried O
to O
assess O
the O
involvement O
of O
the O
p65 O
subunit O
of O
NF-κB O
in O
the O
embryonic O
response O
to O
the O
anti-cancer O
drug O
Doxorubicin O
(DOX) O
. O
Thus O
, O
exposure O
of O
p65 O
knockout O
(p65(-/-)) O
or O
wild O
type O
(WT) O
mouse O

DOX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
cell O
proliferation O
, O
which O
was O
found O
to O
be O
more O
prominent O
in O
p65(-/-) O
MEFs O
. O
Those O
phenomena O
were O
accompanied O
by O
a O
DOX-induced O
increase O
in O
the O
proportion O
of O
apoptotic O
cells O
, O
which O
was O
demonstrated O
only O
in O
p65(-/-) O
cells O
and O
a O
G2/M O
arrest O
, O
which O
was O
found O
to O
be O
more O
prominent O
in O
WT O
cells O
. O
Furthermore O
, O
DOX O
treated O
WT O
and O
p65(-/-) O
MEFs O
differed O
in O
their O
expression O
of O
various O
apoptosis-associated O
molecules O
, O
when O
the O
former O
demonstrated O
a O
decrease O
in O
the O
percentage O
of O
p65-positive O
and O
a O
more O
prominent O
decrease O
in O
the O
percentage O
of O
p53-positive O
cells O
, O
while O
a O
decreased O
percentage O
of O
IκBα-positive O
and O
a O
more O
prominent O
decrease O
in O
the O
percentage O

Glucose O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
G6PC2 O
: O
A O
Negative O
Regulator O
of O
Basal O
Glucos O
-Stimulated O
Insulin B
Secretion.Elevated O
fasting O
blood O
glucose O
(FBG) O
is O
associated O
with O
increased O
risk O
for O
the O
development O
of O
type O
2 O
diabetes O
and O
cardiovascular-associated O
mortality O
. O
Genome-wide O
association O
studies O
(GWAS) O
have O
linked O
polymorphisms O
in O
G6PC2 O
with O
variations O
in O
FBG O
and O
body O
fat O
, O
although O
not O
insulin O
sensitivity O
or O
glucose O
tolerance O
. O
G6PC2 O
encodes O
an O
islet-specific O
, O

glucose O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
deletion O
had O
little O
effect O
on O
insulin B
sensitivity O
and O
glucose O
tolerance O
, O
whereas O
body O
fat O
was O
reduced O
in O
female O
G6pc2 O
knockout O
(KO) O
mice O
on O
both O
a O
chow O
and O
high-fat O
diet O
, O
observations O
that O
are O
all O
consistent O
with O
human O
GWAS O
data O
. O
G6pc2 O
deletion O
resulted O
in O
a O
leftward O
shift O
in O
the O
dose-response O
curve O
for O
glucose O
stimulated O
insulin O
secretion O
(GSIS) O
. O
As O
a O
consequence O
, O
under O
fasting O
conditions O
in O
which O
plasma O
insulin O
levels O
were O
identical O
, O
blood O
glucose O
levels O
were O
reduced O
in O
G6pc2 O
KO O
mice O
, O
again O
consistent O
with O
human O
GWAS O
data O
. O
Glucose-6-phosphatase O
activity O
was O
reduced O
, O
whereas O
basal O
cytoplasmic O
calcium O
levels O
were O
elevated O
in O
islets O
isolated O
from O
G6pc2 O
KO O

glucose-6-phosphate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
glucose O
levels O
were O
reduced O
in O
G6pc2 B
KO O
mice O
, O
again O
consistent O
with O
human O
GWAS O
data O
. O
Glucose-6-phosphatase O
activity O
was O
reduced O
, O
whereas O
basal O
cytoplasmic O
calcium O
levels O
were O
elevated O
in O
islets O
isolated O
from O
G6pc2 O
KO O
mice O
. O
These O
data O
suggest O
that O
G6pc2 O
represents O
a O
novel O
, O
negative O
regulator O
of O
basal O
GSIS O
that O
acts O
by O
hydrolyzing O
glucose-6-phosphate O
thereby O
reducing O
glycolytic O
flux O
. O

Fisetin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated B
hemoglobin I
(HbA1c) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB B
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB O
p65 B
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β B
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

palmatine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
study O
the O
mechanism O
of O
action O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
in O
differentiated O
myocytes O
, O
L6 O
cells O
. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin B
dependent I
glucose I
transporter-4 I
(Glut-4) O
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

palmatine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
study O
the O
mechanism O
of O
action O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
in O
differentiated O
myocytes O
, O
L6 O
cells O
. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin O
dependent O
glucose O
transporter-4 O
(Glut-4) O
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

palmatine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
, O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin B
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

glucose O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
its O
active O
compound O
in O
differentiated O
myocytes O
, O
L6 O
cells O
. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin O
dependent O
glucose O
transporter-4 O
(Glut-4) O
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
, O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Zinc O
drives O
a O
tertiary O
fold O
in O
the O
prion O
protein O
with O
familial O
disease O
mutation O
sites O
at O
the O
interface.The O
cellular O
prion B
protein I
PrP(C) I
consists O
of O
two O
domains--a O
flexible O
N-terminal O
domain O
, O
which O
participates O
in O
copper O
and O
zinc O
regulation O
, O
and O
a O
largely O
helical O
C O
terminal O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) O
function O
and O
misfolding O
in O
disease O
. O
Here O
, O
we O
identify O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) B
function O
and O
misfolding O
in O
disease O
. O
Here O
, O
we O
identify O
a O
Zn²⁺-driven O
N O
terminal O
to O
C-terminal O
tertiary O
interaction O
in O
PrP(C) O
. O
The O
C-terminal O
surface O
participating O
in O
this O
interaction O
carries O
the O
majority O
of O
the O
point O
mutations O
that O
confer O
familial O
prion O
disease O
. O
Investigation O
of O
mutant O
PrPs O
finds O
a O
systematic O
relationship O
between O
the O
type O
of O
mutation O
and O
the O
apparent O
strength O
of O
this O
domain O
structure O
. O
The O
structural O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) B
function O
and O
misfolding O
in O
disease O
. O
Here O
, O
we O
identify O
a O
Zn²⁺-driven O
N-terminal O
to O
C O
terminal O
tertiary O
interaction O
in O
PrP(C) O
. O
The O
C-terminal O
surface O
participating O
in O
this O
interaction O
carries O
the O
majority O
of O
the O
point O
mutations O
that O
confer O
familial O
prion O
disease O
. O
Investigation O
of O
mutant O
PrPs O
finds O
a O
systematic O
relationship O
between O
the O
type O
of O
mutation O
and O
the O
apparent O
strength O
of O
this O
domain O
structure O
. O
The O
structural O
features O
identified O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Zinc O
drives O
a O
tertiary O
fold O
in O
the O
prion O
protein O
with O
familial O
disease O
mutation O
sites O
at O
the O
interface.The O
cellular O
prion B
protein I
PrP(C) I
consists O
of O
two O
domains--a O
flexible O
N O
terminal O
domain O
, O
which O
participates O
in O
copper O
and O
zinc O
regulation O
, O
and O
a O
largely O
helical O
C-terminal O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O

copper O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Zinc O
drives O
a O
tertiary O
fold O
in O
the O
prion O
protein O
with O
familial O
disease O
mutation O
sites O
at O
the O
interface.The O
cellular O
prion B
protein I
PrP(C) I
consists O
of O
two O
domains--a O
flexible O
N-terminal O
domain O
, O
which O
participates O
in O
copper O
and O
zinc O
regulation O
, O
and O
a O
largely O
helical O
C-terminal O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) O
function O

zinc O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Zinc O
drives O
a O
tertiary O
fold O
in O
the O
prion O
protein O
with O
familial O
disease O
mutation O
sites O
at O
the O
interface.The O
cellular O
prion B
protein I
PrP(C) I
consists O
of O
two O
domains--a O
flexible O
N-terminal O
domain O
, O
which O
participates O
in O
copper O
and O
zinc O
regulation O
, O
and O
a O
largely O
helical O
C-terminal O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) O
function O
and O
misfolding O

Zn²⁺ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) B
function O
and O
misfolding O
in O
disease O
. O
Here O
, O
we O
identify O
a O
Zn²⁺ O
driven O
N-terminal O
to O
C-terminal O
tertiary O
interaction O
in O
PrP(C) O
. O
The O
C-terminal O
surface O
participating O
in O
this O
interaction O
carries O
the O
majority O
of O
the O
point O
mutations O
that O
confer O
familial O
prion O
disease O
. O
Investigation O
of O
mutant O
PrPs O
finds O
a O
systematic O
relationship O
between O
the O
type O
of O
mutation O
and O
the O
apparent O
strength O
of O
this O
domain O
structure O
. O
The O

fluoride O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
opening O
of O
cell O
junctions O
, O
presence O
of O
anions) O
. O
The O
results O
indicate O
that O
fluoride O
is O
an O
element O
with O
moderate O
absorption O
(<70%) O
in O
both O
directions O
(absorptive O
and O
secretory) O
. O
Both O
in O
absorption O
(apical-basolateral) O
and O
in O
secretion O
(basolateral-apical) O
there O
is O
transport O
by O
the O
paracellular O
pathway O
, O
which O
may O
be O
considered O
predominant O
. O
Absorption O
and O
secretion O
of O
fluoride O
increase O
at O
acid O
pH O
levels O
, O
possibly O
because O
of O
its O
non-ionized O
state O
at O
these O
pHs O
and/or O
because O
of O
participation O
of O
a O
F(-)/H(+) O
cotransporter O
or O
a O
F(-)/OH(-) O
antiporter O
. O
The O
results O
also O
suggest O
transcellular O
participation O
of O
mechanisms O
involved O
in O
transport O
of O
Cl(-) O
and O
of O
an O
active O
transport O
in O
the O
secretory O
direction O
. O
The O

fluoride O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
opening O
of O
cell O
junctions O
, O
presence O
of O
anions) O
. O
The O
results O
indicate O
that O
fluoride O
is O
an O
element O
with O
moderate O
absorption O
(<70%) O
in O
both O
directions O
(absorptive O
and O
secretory) O
. O
Both O
in O
absorption O
(apical-basolateral) O
and O
in O
secretion O
(basolateral-apical) O
there O
is O
transport O
by O
the O
paracellular O
pathway O
, O
which O
may O
be O
considered O
predominant O
. O
Absorption O
and O
secretion O
of O
fluoride O
increase O
at O
acid O
pH O
levels O
, O
possibly O
because O
of O
its O
non-ionized O
state O
at O
these O
pHs O
and/or O
because O
of O
participation O
of O
a O
F(-)/H(+) B
cotransporter I
or O
a O
F(-)/OH(-) O
antiporter O
. O
The O
results O
also O
suggest O
transcellular O
participation O
of O
mechanisms O
involved O
in O
transport O
of O
Cl(-) O
and O
of O
an O
active O
transport O
in O
the O
secretory O
direction O
. O
The O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Nuclear O
receptor O
CAR O
specifically O
activates O
the O
two-pore O
K+ O
channel O
Kcnk1 O
gene O
in O
male O
mouse O
livers O
, O
which O
attenuates O
phenobarbital-induced O
hepatic O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 B
as O
a O
phenobarbital-inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
, O
nuclear O
receptor O
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Nuclear O
receptor O
CAR O
specifically O
activates O
the O
two-pore O
K+ O
channel O
Kcnk1 O
gene O
in O
male O
mouse O
livers O
, O
which O
attenuates O
phenobarbital-induced O
hepatic O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital-inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
, O
nuclear O
receptor O
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
mouse O
livers O
, O
which O
attenuates O
phenobarbital-induced O
hepatic O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 B
as O
a O
phenobarbital O
inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
, O
nuclear O
receptor O
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O
male O
mice O
, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital-inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
nuclear B
receptor I
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O
male O
mice O
, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O
progressed O
in O
the O
livers O
of O
Kcnk1 O
( O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital-inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
nuclear O
receptor O
CAR B
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O
male O
mice O
, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O
progressed O
in O
the O
livers O
of O
Kcnk1 O
( O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O
progressed O
in O
the O
livers O
of O
Kcnk1 O
( O
-/- O
) O
male O
mice O
compared O
with O
those O
of O
Kcnk1 O
( O
+/+ O
) O
males O
after O
phenobarbital O
treatment O
. O
Thus O
, O
KCNK1 B
suppresses O
phenobarbital-induced O
hyperplasia O
. O
These O
results O
indicate O
that O
phenobarbital O
treatment O
induces O
KCNK1 O
to O
elicit O
a O
male-specific O
and O
growth-suppressing O
signal O
. O
Thus O
, O
KCNK1 O
and O
Kcnk1 O
( O
-/- O
) O
mice O
provide O
an O
experimental O
tool O
for O
further O
investigation O
into O
the O
molecular O
mechanism O
of O
CAR-mediated O
promotion O
of O
the O
development O
of O
hepatocellular O
carcinoma O
in O
mice O
. O

phenobarbital O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
mouse O
livers O
, O
which O
attenuates O
phenobarbital-induced O
hepatic O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 B
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital O
inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
, O
nuclear O
receptor O
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O
male O
mice O
, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O

navitoclax O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
CLL/lymphoma O
2 O
(BCL-2) O
family O
are O
key O
regulators O
of O
the O
apoptotic O
process O
. O
This O
family O
comprises O
proapoptotic O
and O
prosurvival O
proteins O
, O
and O
shifting O
the O
balance O
toward O
the O
latter O
is O
an O
established O
mechanism O
whereby O
cancer O
cells O
evade O
apoptosis O
. O
The O
therapeutic O
potential O
of O
directly O
inhibiting O
prosurvival O
proteins O
was O
unveiled O
with O
the O
development O
of O
navitoclax O
a O
selective O
inhibitor O
of O
both O
BCL-2 B
and O
BCL-2-like O
1 O
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) O
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O

navitoclax O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
CLL/lymphoma O
2 O
(BCL-2) O
family O
are O
key O
regulators O
of O
the O
apoptotic O
process O
. O
This O
family O
comprises O
proapoptotic O
and O
prosurvival O
proteins O
, O
and O
shifting O
the O
balance O
toward O
the O
latter O
is O
an O
established O
mechanism O
whereby O
cancer O
cells O
evade O
apoptosis O
. O
The O
therapeutic O
potential O
of O
directly O
inhibiting O
prosurvival O
proteins O
was O
unveiled O
with O
the O
development O
of O
navitoclax O
a O
selective O
inhibitor O
of O
both O
BCL-2 O
and O
BCL-2-like B
1 I
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) O
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O

navitoclax O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
CLL/lymphoma O
2 O
(BCL-2) O
family O
are O
key O
regulators O
of O
the O
apoptotic O
process O
. O
This O
family O
comprises O
proapoptotic O
and O
prosurvival O
proteins O
, O
and O
shifting O
the O
balance O
toward O
the O
latter O
is O
an O
established O
mechanism O
whereby O
cancer O
cells O
evade O
apoptosis O
. O
The O
therapeutic O
potential O
of O
directly O
inhibiting O
prosurvival O
proteins O
was O
unveiled O
with O
the O
development O
of O
navitoclax O
a O
selective O
inhibitor O
of O
both O
BCL-2 O
and O
BCL-2-like O
1 O
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) B
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O

navitoclax O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
proteins O
was O
unveiled O
with O
the O
development O
of O
navitoclax O
, O
a O
selective O
inhibitor O
of O
both O
BCL-2 B
and O
BCL-2-like O
1 O
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) O
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O
and O
BCL-2-selective O
inhibitor O
, O
ABT-199 O
. O
This O
compound O
inhibits O
the O
growth O
of O
BCL-2-dependent O
tumors O
in O
vivo O
and O
spares O
human O
platelets O
. O
A O
single O
dose O
of O
ABT-199 O
in O
three O
patients O
with O
refractory O
chronic O
lymphocytic O
leukemia O
resulted O
in O
tumor O
lysis O
within O
24 O
h O
. O
These O
data O
indicate O
that O

ABT-199 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
both O
BCL-2 B
and O
BCL-2-like O
1 O
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) O
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O
and O
BCL-2-selective O
inhibitor O
, O
ABT-199 O
This O
compound O
inhibits O
the O
growth O
of O
BCL-2-dependent O
tumors O
in O
vivo O
and O
spares O
human O
platelets O
. O
A O
single O
dose O
of O
ABT-199 O
in O
three O
patients O
with O
refractory O
chronic O
lymphocytic O
leukemia O
resulted O
in O
tumor O
lysis O
within O
24 O
h O
. O
These O
data O
indicate O
that O
selective O
pharmacological O
inhibition O
of O
BCL-2 O
shows O
promise O
for O
the O
treatment O
of O

aflatoxin O
B(1) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
TA1537 O
and O
WP2 O
strains O
were O
37.70% O
and O
69.70% O
, O
respectively O
. O
According O
to O
the O
SCE O
test O
system O
, O
MEP O
reduced O
the O
genotoxic O
effects O
of O
aflatoxin O
. O
In O
order O
to O
clarify O
the O
mechanism O
underlying O
the O
antigenotoxic O
effects O
of O
MEP O
, O
the O
antioxidants O
were O
determined O
. O
Cotreatments O
of O
5 O
, O
10 O
and O
20 O
µg/mL O
concentrations O
of O
MEP O
with O
aflatoxin O
B(1) O
decreased O
the O
frequencies O
of O
SCE O
and O
the O
malondialdehyde O
level O
and O
increased O
amount O
of O
superoxide O
dismutase O
, O
glutathione O
and O
glutathione O
peroxidase O
which O
were O
decreased O
by O
aflatoxin O
. O
The O
data O
obtained O
from O
this O
work O
have O
clearly O
shown O
that O
MEP O
has O
significant O
antigenotoxic O
effects O
which O
are O
thought O
to O
be O
partly O
due O
to O
the O
antioxidant O

aflatoxin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
clarify O
the O
mechanism O
underlying O
the O
antigenotoxic O
effects O
of O
MEP O
, O
the O
antioxidants O
were O
determined O
. O
Cotreatments O
of O
5 O
, O
10 O
and O
20 O
µg/mL O
concentrations O
of O
MEP O
with O
aflatoxin O
B(1) O
decreased O
the O
frequencies O
of O
SCE O
and O
the O
malondialdehyde O
level O
and O
increased O
amount O
of O
superoxide O
dismutase O
, O
glutathione O
and O
glutathione B
peroxidase I
which O
were O
decreased O
by O
aflatoxin O
The O
data O
obtained O
from O
this O
work O
have O
clearly O
shown O
that O
MEP O
has O
significant O
antigenotoxic O
effects O
which O
are O
thought O
to O
be O
partly O
due O
to O
the O
antioxidant O
activities O
and O
antioxidant O
inducing O
capability O
of O
MEP O
. O
This O
is O
the O
first O
report O
indicating O
the O
antigenotoxic O
activities O
of O
MEP O
against O
several O
mutagen O
agents O
such O
as O

atRA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
early O
stage O
of O
cell O
adhesion O
by O
atRA O
treatment O
. O
Re-expression O
of O
COL8A2 B
in O
COL8A2-knocked-down O
HCC O
cells O
reversed O
the O
effect O
of O
small O
interfering O
RNA-COL8A2 O
. O
In O
addition O
, O
COL8A2 O
could O
increase O
HCC O
cell O
migration O
and O
invasion O
. O
Thus O
, O
COL8A2 O
was O
identified O
as O
the O
key O
protein O
involved O
in O
the O
enhancement O
of O
cell O
adhesion O
of O
atRA O
under O
serum-free O
conditions O
. O
In O
conclusion O
, O
atRA O
protects O
HCC O
cells O
against O
serum-starvation-induced O
cell O
death O
by O
enhancing O
cell O
adhesion O
, O
and O
COL8A2 O
plays O
an O
important O
role O
in O
HCC O
cell O
migration O
and O
invasion O
. O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
this O
early O
short-term O
treatment O
with O
PGE2 O
. O
Interestingly O
, O
a O
Th2 O
response O
was O
already O
committed O
on O
day O
5 O
of O
exposure O
to O
HDM O
. O
This O
was O
paralleled O
by O
GM-CSF O
and O
osteopontin O
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O
T O
regulatory O
cells O
, O
as O
well O
as O
a O
trend O
towards O
reduced O
IL-10 O
expression O
. O
Local O
PGE2 O
administration O
prevented O
the O
increase O
of O
airway O
IL-13 B
and O
osteopontin O
and O
kept O
lung O
plasmacytoid O
dendritic O
cell O
counts O
close O
to O
baseline O
. O
GM-CSF O
and O
Tregs O
were O
unaffected O
by O
the O
treatment O
. O
These O
findings O
suggest O
that O
the O
protection O
provided O
by O
PGE2 O
is O
a O
result O
of O
the O
modulation O
of O
early O
lung O
immunomodulatory O
mechanisms O
, O
and O
possibly O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
this O
early O
short-term O
treatment O
with O
PGE2 O
. O
Interestingly O
, O
a O
Th2 O
response O
was O
already O
committed O
on O
day O
5 O
of O
exposure O
to O
HDM O
. O
This O
was O
paralleled O
by O
GM-CSF O
and O
osteopontin B
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O
T O
regulatory O
cells O
, O
as O
well O
as O
a O
trend O
towards O
reduced O
IL-10 O
expression O
. O
Local O
PGE2 O
administration O
prevented O
the O
increase O
of O
airway O
IL-13 O
and O
osteopontin O
and O
kept O
lung O
plasmacytoid O
dendritic O
cell O
counts O
close O
to O
baseline O
. O
GM-CSF O
and O
Tregs O
were O
unaffected O
by O
the O
treatment O
. O
These O
findings O
suggest O
that O
the O
protection O
provided O
by O
PGE2 O
is O
a O
result O
of O
the O
modulation O
of O
early O
lung O
immunomodulatory O
mechanisms O
, O
and O
possibly O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
cytokine O
production O
were O
analysed O
by O
flow O
cytometry O
and O
ELISA O
, O
respectively O
. O
Airway O
hyperreactivity O
was O
sustainably O
reduced O
only O
when O
PGE2 O
administration O
was O
restricted O
to O
the O
initial O
5 O
days O
of O
exposure O
to O
HDM O
. O
Lung O
inflammation O
, O
IL-4 B
production O
, O
and O
airway O
mast O
cell O
activity O
were O
also O
prevented O
under O
this O
early O
short-term O
treatment O
with O
PGE2 O
Interestingly O
, O
a O
Th2 O
response O
was O
already O
committed O
on O
day O
5 O
of O
exposure O
to O
HDM O
. O
This O
was O
paralleled O
by O
GM-CSF O
and O
osteopontin O
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O
T O
regulatory O
cells O
, O
as O
well O
as O
a O
trend O
towards O
reduced O
IL-10 O
expression O
. O
Local O
PGE2 O
administration O
prevented O
the O
increase O
of O

TAK-441 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog O
inhibitor O
TAK-441 O
for O
the O
inhibition O
of O
Gli1 O
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
( O
TAK-441 O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo B
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK-441 O
and O
the O
responses O
of O
Gli1 O
mRNA O
in O
tumor-associated O

TAK-441 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK-441 O
and O
the O
responses O
of O
Gli1 B
mRNA O
in O
tumor-associated O
stromal O
or O
skin O
cells O
and O
the O
antitumor O
effect O
of O
hedgehog O
inhibition O
. O
To O
this O
end O
, O
we O
built O
pharmacokinetic O
and O
pharmacodynamic O
models O
that O
describe O
the O
relationship O
of O
the O
concentrations O
of O
TAK-441 O
plasma O
to O
the O
responses O
of O
Gli1 O
mRNA O
in O
the O
tumor O
(target) O
and O
skin O
(surrogate) O
and O
to O
tumor O
growth O
inhibition O
in O
mice O
bearing O
xenografts O
of O
human O
pancreatic O
tumors O
(PAN-04) O
. O
The O
responses O
of O
Gli1 O
mRNA O
and O
tumor O
growth O
were O
described O
by O
an O
indirect O
response O
model O
and O
an O
exponential O
tumor O
growth O
model O
, O

TAK-441 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
to O
tumor O
growth O
inhibition O
in O
mice O
bearing O
xenografts O
of O
human O
pancreatic O
tumors O
(PAN-04) O
. O
The O
responses O
of O
Gli1 B
mRNA O
and O
tumor O
growth O
were O
described O
by O
an O
indirect O
response O
model O
and O
an O
exponential O
tumor O
growth O
model O
, O
respectively O
. O
The O
IC50 O
values O
for O
Gli1 O
mRNA O
inhibition O
in O
the O
tumor O
and O
skin O
by O
TAK-441 O
were O
estimated O
to O
be O
0.0457 O
and O
0.113 O
μg/ml O
, O
respectively O
. O
The O
IC90 O
value O
for O
tumor O
growth O
inhibition O
was O
estimated O
to O
be O
0.68 O
μg/ml O
. O
These O
results O
suggest O
that O
a O
>83% O
inhibition O
of O
Gli1 O
mRNA O
expression O
in O
the O
skin O
or O
a O
>94% O
inhibition O
of O
Gli1 O
mRNA O
expression O
in O
the O
tumor O
would O
be O

TAK-441 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog O
inhibitor O
TAK-44 O
for O
the O
inhibition O
of O
Gli1 B
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
(TAK-441) O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo O
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O

TAK-441 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog B
inhibitor O
TAK-441 O
for O
the O
inhibition O
of O
Gli1 O
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
( O
TAK-441 O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo O
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK-441 O
and O
the O
responses O
of O
Gli1 O
mRNA O
in O
tumor-associated O

TAK-441 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog B
inhibitor O
TAK-44 O
for O
the O
inhibition O
of O
Gli1 O
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
(TAK-441) O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo O
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O

poly(ethylene O
glycol) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
We O
demonstrate O
that O
single-walled O
CNTs O
coated O
with O
human O
serum O
albumin O
activate O
the O
complement O
system O
through O
C1q-mediated O
classical O
and O
the O
alternative O
pathways O
. O
Surface O
coating O
with O
methoxypoly(ethylene O
glycol)-based O
amphiphiles O
, O
which O
confers O
solubility O
and O
prolongs O
circulation O
profiles O
of O
CNTs O
, O
activates O
the O
complement O
system O
differently O
, O
depending O
on O
the O
amphiphile O
structure O
. O
CNTs O
with O
linear O
poly(ethylene O
glycol) O
amphiphiles O
trigger O
the O
lectin B
pathway O
of O
the O
complement O
through O
both O
L-ficolin O
and O
mannan-binding O
lectin O
recognition O
. O
The O
lectin O
pathway O
activation O
, O
however O
, O
did O
not O
trigger O
the O
amplification O
loop O
of O
the O
alternative O
pathway O
. O
An O
amphiphile O
with O
branched O
poly(ethylene O
glycol) O
architecture O
also O
activated O
the O
lectin O
pathway O
but O
only O
through O
L-ficolin O
recognition O
. O
Importantly O
, O
this O

poly(ethylene O
glycol) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
We O
demonstrate O
that O
single-walled O
CNTs O
coated O
with O
human O
serum O
albumin O
activate O
the O
complement O
system O
through O
C1q-mediated O
classical O
and O
the O
alternative O
pathways O
. O
Surface O
coating O
with O
methoxypoly(ethylene O
glycol)-based O
amphiphiles O
, O
which O
confers O
solubility O
and O
prolongs O
circulation O
profiles O
of O
CNTs O
, O
activates O
the O
complement O
system O
differently O
, O
depending O
on O
the O
amphiphile O
structure O
. O
CNTs O
with O
linear O
poly(ethylene O
glycol) O
amphiphiles O
trigger O
the O
lectin B
pathway O
of O
the O
complement O
through O
both O
L-ficolin O
and O
mannan-binding O
lectin O
recognition O
. O
The O
lectin O
pathway O
activation O
, O
however O
, O
did O
not O
trigger O
the O
amplification O
loop O
of O
the O
alternative O
pathway O
. O
An O
amphiphile O
with O
branched O
poly(ethylene O
glycol) O
architecture O
also O
activated O
the O
lectin O
pathway O
but O
only O
through O
L-ficolin O
recognition O
. O
Importantly O
, O
this O

poly(ethylene O
glycol) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activates O
the O
complement O
system O
differently O
, O
depending O
on O
the O
amphiphile O
structure O
. O
CNTs O
with O
linear O
poly(ethylene O
glycol) O
amphiphiles O
trigger O
the O
lectin B
pathway O
of O
the O
complement O
through O
both O
L-ficolin O
and O
mannan-binding O
lectin O
recognition O
. O
The O
lectin O
pathway O
activation O
, O
however O
, O
did O
not O
trigger O
the O
amplification O
loop O
of O
the O
alternative O
pathway O
. O
An O
amphiphile O
with O
branched O
poly(ethylene O
glycol) O
architecture O
also O
activated O
the O
lectin O
pathway O
but O
only O
through O
L-ficolin O
recognition O
. O
Importantly O
, O
this O
mode O
of O
activation O
neither O
generated O
anaphylatoxins O
nor O
induced O
triggering O
of O
the O
effector O
arm O
of O
the O
complement O
system O
. O
These O
observations O
provide O
a O
major O
step O
toward O
nanomaterial O
surface O
modification O
with O
polymers O
that O
have O
the O
properties O
to O
significantly O
improve O

perviridicin O
B O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
line O
, O
with O
rocaglaol O
(9) O
being O
the O
most O
potent O
(ED50 O
0.0007 O
μM) O
. O
The O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB B
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

perviridicin O
B O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
line O
, O
with O
rocaglaol O
(9) O
being O
the O
most O
potent O
(ED50 O
0.0007 O
μM) O
. O
The O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB O
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

rocaglate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
being O
the O
most O
potent O
(ED50 O
0.0007 O
μM) O
. O
The O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB B
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

rocaglate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
being O
the O
most O
potent O
(ED50 O
0.0007 O
μM) O
. O
The O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB O
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

sesquiterpene O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB B
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

sesquiterpene O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB O
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

2-oxaisodauc-5-en-12-al O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB B
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

2-oxaisodauc-5-en-12-al O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB O
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

sulforaphane O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 B
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane O
inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O
cell O
line O
THP-1 O
as O
well O
as O
in O
human O
primary O
blood O
CD14(+) O
monocytes O
. O
In O
conclusion O
, O
together O
with O
the O
high O
inducibility O

sulforaphane O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O

sulforaphane O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O

tert-butylhydroquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O

tert-butylhydroquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O

cinnamic O
aldehyde O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O

cinnamic O
aldehyde O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O

hydrogen O
peroxide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O

hydrogen O
peroxide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O

sulforaphane O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Secondly O
, O
the O
linkage O
between O
NRF2 B
and O
the O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 O
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane-inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O

sulforaphane O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto B
reductase I
(AKR) I
1C1 I
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O

tert-butylhydroquinone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto B
reductase I
(AKR) I
1C1 I
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O

cinnamic O
aldehyde O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto B
reductase I
(AKR) I
1C1 I
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O

hydrogen O
peroxide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide O
showed O
that O
the O
aldo-keto B
reductase I
(AKR) I
1C1 I
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O

sulforaphane O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Secondly O
, O
the O
linkage O
between O
NRF2 O
and O
the O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 O
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane-inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O

sulforaphane O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 O
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane O
inducible O
expression O
of O
AKR1C1 B
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O
cell O
line O
THP-1 O
as O
well O
as O
in O
human O
primary O
blood O
CD14(+) O
monocytes O
. O
In O
conclusion O
, O
together O
with O
the O
high O
inducibility O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
ends O
by O
facilitating O
their O
organization O
into O
the O
protective O
capping O
structure O
. O
Post-translational O
modifications O
of O
TRF2 B
such O
as O
phosphorylation O
, O
ubiquitination O
, O
SUMOylation O
, O
methylation O
and O
poly(ADP-ribosyl)ation O
have O
been O
shown O
to O
play O
important O
roles O
in O
telomere O
function O
. O
Here O
we O
show O
that O
TRF2 O
specifically O
interacts O
with O
the O
histone O
acetyltransferase O
p300 O
, O
and O
that O
p300 O
acetylates O
the O
lysine O
residue O
at O
position O
293 O
of O
TRF2 O
. O
We O
also O
report O
that O
p300-mediated O
acetylation O
stabilizes O
the O
TRF2 O
protein O
by O
inhibiting O
its O
ubiquitin-dependent O
proteolysis O
and O
is O
required O
for O
efficient O
telomere O
binding O
of O
TRF2 O
. O
Furthermore O
, O
overexpression O
of O
the O
acetylation-deficient O
mutant O
, O
K293R O
, O
induces O
DNA-damage O
response O
foci O
at O
telomeres O
, O
thereby O
leading O
to O
induction O
of O
impaired O

Tyr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 B
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 B
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 B
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 B
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 B
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL B
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 B
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O

AG490 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

AG490 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
down-regulated O
the O
expression O
of O
STAT3 B
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

GW4064 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
Baat) O
, O
whereas O
Bsep O
, O
Mrp2 O
and O
Cyp27a1 O
were O
up-regulated O
. O
Human O
HepG2 O
and O
Alexander O
cell O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR B
expression O
, O
respectively O
. O
In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 O
on O
FXR-target O
genes O
. O
In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR O
, O
GW4064 O
caused O
up-regulation O
of O
SHP O
and O
OSTβ O
, O
and O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR O
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O

GW4064 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR B
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR O
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR O
activity O
. O
Moreover O
, O
GCs O
have O
a O
synergistic O
effect O
on O
GW4064 O
induced O
FXR O
activation O
, O
whereas O
chenodeoxycholate O
and O
GW4064 O
have O
an O
additive O
effect O
. O
In O
conclusion O
, O
GCs O
are O
able O
to O
directly O
or O
indirectly O
activate O
FXR O
but O
they O
also O
antagonize O
, O
through O
FXR-independent O
mechanisms O
, O
the O
expression O
of O
FXR O
and O
FXR O
target O
genes O
involved O
in O
the O
hepatic O
handling O
of O
BAs O
. O

GW4064 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR O
expression O
, O
respectively O
. O
In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 O
on O
FXR-target O
genes O
. O
In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR O
, O
GW4064 O
caused O
up-regulation O
of O
SHP B
and O
OSTβ O
, O
and O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR O
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR O
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR O
activity O
. O

GW4064 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR O
expression O
, O
respectively O
. O
In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 O
on O
FXR-target O
genes O
. O
In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR O
, O
GW4064 O
caused O
up-regulation O
of O
SHP O
and O
OSTβ O
, O
and O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR O
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR O
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR O
activity O
. O

GW4064 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR O
expression O
, O
respectively O
. O
In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 O
on O
FXR-target O
genes O
. O
In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR O
, O
GW4064 O
caused O
up-regulation O
of O
SHP O
and O
OSTβ O
, O
and O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR O
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR O
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR O
activity O
. O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn-induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced O
DA O
release O
and O
loss O
of O
the O
dopamine O
transporter O
(DAT) O
. O
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn O
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected O
HEK O
cells O
reveal O
that O
Mn O
is O
equally O
toxic O
to O
both O
cell O
lines O
whereas O
DA O
was O
only O
toxic O
to O
cells O
containing O
DAT O
. O
DA O
toxicity O
was O
saturable O
suggesting O
that O
transport O
may O
be O
rate O
limiting O
. O
When O
Mn O
and O
DA O
were O
added O
simultaneously O
to O
the O
media O
, O
cell O
toxicity O
was O
similar O
to O
that O
produced O
by O
Mn O
alone O
suggesting O
that O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
media O
, O
cell O
toxicity O
was O
similar O
to O
that O
produced O
by O
Mn O
alone O
suggesting O
that O
Mn O
may O
suppress O
DA O
uptake O
in O
the O
DAT B
containing O
cells O
. O
Preincubation O
of O
DA O
prior O
to O
the O
addition O
of O
Mn O
resulted O
in O
cell O
death O
which O
was O
essentially O
additive O
with O
that O
produced O
independently O
by O
the O
two O
agents O
. O
Mn O
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced O
DA O
efflux O
in O
DAT O
containing O
cells O
. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn O
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells O
. O
Mn-induced O
internalization O
of O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
DAT B
containing O
cells O
. O
Preincubation O
of O
DA O
prior O
to O
the O
addition O
of O
Mn O
resulted O
in O
cell O
death O
which O
was O
essentially O
additive O
with O
that O
produced O
independently O
by O
the O
two O
agents O
. O
Mn O
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced O
DA O
efflux O
in O
DAT O
containing O
cells O
. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn O
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells O
. O
Mn-induced O
internalization O
of O
DAT O
may O
provide O
an O
explanation O
for O
disruption O
in O
DA O
transmission O
previously O
reported O
in O
the O
striatum O
. O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
two O
agents O
. O
Mn O
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced O
DA O
efflux O
in O
DAT B
containing O
cells O
. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn O
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells O
. O
Mn O
induced O
internalization O
of O
DAT O
may O
provide O
an O
explanation O
for O
disruption O
in O
DA O
transmission O
previously O
reported O
in O
the O
striatum O
. O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
effect O
of O
manganese O
on O
dopamine O
toxicity O
and O
dopamine B
transporter I
(DAT) O
in O
control O
and O
DAT O
transfected O
HEK O
cells.Chronic O
exposure O
to O
Mn O
results O
in O
the O
development O
of O
a O
neurological O
disorder O
known O
as O
manganism O
characterized O
by O
neurological O
deficits O
resembling O
that O
seen O
in O
Parkinsonism O
. O
Although O
dopaminergic O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn O
induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced O
DA O
release O
and O
loss O
of O
the O
dopamine O
transporter O
(DAT) O
. O
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn O
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected O
HEK O
cells O
reveal O
that O
Mn O
is O
equally O
toxic O
to O
both O
cell O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
effect O
of O
manganese O
on O
dopamine O
toxicity O
and O
dopamine O
transporter O
(DAT) O
in O
control O
and O
DAT B
transfected O
HEK O
cells.Chronic O
exposure O
to O
Mn O
results O
in O
the O
development O
of O
a O
neurological O
disorder O
known O
as O
manganism O
characterized O
by O
neurological O
deficits O
resembling O
that O
seen O
in O
Parkinsonism O
. O
Although O
dopaminergic O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn O
induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced O
DA O
release O
and O
loss O
of O
the O
dopamine O
transporter O
(DAT) O
. O
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn O
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected O
HEK O
cells O
reveal O
that O
Mn O
is O
equally O
toxic O
to O
both O
cell O

2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridin O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O

2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridin O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun B
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O

2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridin O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 B
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O

PhIP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhI O
) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O

PhIP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhI O
) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun B
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O

PhIP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhI O
) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 B
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O

PhIP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos B
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

PhIP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun B
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

PhIP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun B
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O

PhIP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos B
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O

PhIP O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase B
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide B
dismutase I
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase B
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 B
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O

PhIP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 B
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium O
dimethanesulfonate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
pharmacokinetic O
model O
for O
the O
oxime O
TMB-4 O
: O
simulation O
of O
rodent O
and O
human O
data.Multiple O
oximes O
have O
been O
synthesized O
and O
evaluated O
for O
use O
as O
countermeasures O
against O
chemical O
warfare O
nerve O
agents O
. O
The O
current O
U.S O
. O
military O
and O
civilian O
oxime O
countermeasure O
, O
2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium O
chloride O
(2-PAM) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase B
reactivator O
, O
1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium O
dimethanesulfonate O
(MMB-4) O
. O
Kinetic O
data O
in O
the O
scientific O
literature O
for O
MMB-4 O
are O
limited; O
therefore O
, O
a O
physiologically O
based O
pharmacokinetic O
(PBPK) O
model O
was O
developed O
for O
a O
structurally O
related O
oxime O
, O
1,1'-trimethylenebis{4-hydroximinomethyl}pyridinium O
dibromide O
. O
Based O
on O
a O
previous O
model O
structure O
for O
the O
organophosphate O
diisopropylfluorophosphate O
, O
the O
model O
includes O
key O
sites O
of O
acetylcholinesterase O
inhibition O
(brain O
and O
diaphragm) O
, O
as O

MMB-4 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
oxime O
TMB-4 O
: O
simulation O
of O
rodent O
and O
human O
data.Multiple O
oximes O
have O
been O
synthesized O
and O
evaluated O
for O
use O
as O
countermeasures O
against O
chemical O
warfare O
nerve O
agents O
. O
The O
current O
U.S O
. O
military O
and O
civilian O
oxime O
countermeasure O
, O
2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium O
chloride O
(2-PAM) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase B
reactivator O
, O
1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium O
dimethanesulfonate O
( O
MMB-4 O
 O
. O
Kinetic O
data O
in O
the O
scientific O
literature O
for O
MMB-4 O
are O
limited; O
therefore O
, O
a O
physiologically O
based O
pharmacokinetic O
(PBPK) O
model O
was O
developed O
for O
a O
structurally O
related O
oxime O
, O
1,1'-trimethylenebis{4-hydroximinomethyl}pyridinium O
dibromide O
. O
Based O
on O
a O
previous O
model O
structure O
for O
the O
organophosphate O
diisopropylfluorophosphate O
, O
the O
model O
includes O
key O
sites O
of O
acetylcholinesterase O
inhibition O
(brain O
and O
diaphragm) O
, O
as O

SiO(2) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 B
and O
caspase-9 O
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O
and O
A549 O
cells O
, O
which O
is O
likely O
to O
be O
mediated O
through O
ROS O
generation O
and O
oxidative O
stress O
. O

SiO(2) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 O
and O
caspase-9 B
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O
and O
A549 O
cells O
, O
which O
is O
likely O
to O
be O
mediated O
through O
ROS O
generation O
and O
oxidative O
stress O
. O

SiO(2) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) O
and O
lactate O
dehydrogenase O
leakage O
assays O
. O
SiO(2) O
NPs O
were O
also O
found O
to O
induce O
oxidative O
stress O
in O
a O
dose-dependent O
manner O
, O
indicated O
by O
depletion O
of O
glutathione O
and O
induction O
of O
reactive O
oxygen O
species O
(ROS) O
generation O
and O
lipid O
peroxidation O
. O
Quantitative O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 B
and O
caspase-9 O
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O

SiO(2) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) O
and O
lactate O
dehydrogenase O
leakage O
assays O
. O
SiO(2) O
NPs O
were O
also O
found O
to O
induce O
oxidative O
stress O
in O
a O
dose-dependent O
manner O
, O
indicated O
by O
depletion O
of O
glutathione O
and O
induction O
of O
reactive O
oxygen O
species O
(ROS) O
generation O
and O
lipid O
peroxidation O
. O
Quantitative O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 O
and O
caspase-9 B
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
four O
new O
mouse O
cytochrome O
P450 O
enzymes O
of O
the O
CYP2J B
subfamily.The O
cytochrome O
P450 O
superfamily O
encompasses O
a O
diverse O
group O
of O
enzymes O
that O
catalyze O
the O
oxidation O
of O
various O
substrates O
. O
The O
mouse O
CYP2J O
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic O
acid O
(AA) O
, O
linoleic O
acid O
(LA) O
, O
and O
other O
lipids O
and O
xenobiotics O
. O
The O
mouse O
Cyp2j O
locus O
contains O
seven O
genes O
and O
three O
pseudogenes O
located O
in O
a O
contiguous O
0.62 O
megabase O
cluster O
on O
chromosome O
4 O
. O
We O
describe O
four O
new O
mouse O
CYP2J O
isoforms O
(designated O
CYP2J8 O
, O
CYP2J11 O
, O
CYP2J12 O
, O
and O
CYP2J13) O
. O
The O
four O
cDNAs O
contain O
open O
reading O
frames O

linoleic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
four O
new O
mouse O
cytochrome O
P450 O
enzymes O
of O
the O
CYP2J B
subfamily.The O
cytochrome O
P450 O
superfamily O
encompasses O
a O
diverse O
group O
of O
enzymes O
that O
catalyze O
the O
oxidation O
of O
various O
substrates O
. O
The O
mouse O
CYP2J O
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic O
acid O
(AA) O
, O
linoleic O
acid O
(LA) O
, O
and O
other O
lipids O
and O
xenobiotics O
. O
The O
mouse O
Cyp2j O
locus O
contains O
seven O
genes O
and O
three O
pseudogenes O
located O
in O
a O
contiguous O
0.62 O
megabase O
cluster O
on O
chromosome O
4 O
. O
We O
describe O
four O
new O
mouse O
CYP2J O
isoforms O
(designated O
CYP2J8 O
, O
CYP2J11 O
, O
CYP2J12 O
, O
and O
CYP2J13) O
. O
The O
four O
cDNAs O
contain O
open O
reading O
frames O
that O
encode O
polypeptides O

doxycycline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
renin-angiotensin-aldosterone O
system O
and O
oxidative O
stress O
activate O
and O
upregulate O
MMPs O
. O
Therefore O
, O
MMP B
inhibition O
may O
prevent O
the O
deleterious O
consequences O
of O
hypertension O
to O
the O
cardiovascular O
system O
. O
This O
review O
article O
will O
focus O
on O
growing O
evidence O
supporting O
the O
relevance O
of O
MMPs O
in O
hypertension O
and O
the O
effects O
of O
MMP O
inhibitors O
. O
Particularly O
, O
the O
effects O
of O
doxycycline O
used O
as O
a O
non O
selective O
MMP O
inhibitor O
in O
experimental O
and O
clinical O
studies O
will O
be O
discussed O
. O

TES O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O

TES O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O

TES O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O

TES O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen B
receptor I
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O

peroxynitrite O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase-generated O
superoxide O
and O
NO O
. O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

superoxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase-generated O
superoxide O
and O
NO O
. O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase-generated O
superoxide O
and O
NO O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

TES O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
and O
nitrotyrosine O
immunoblot O
experiments O
indicated O
that O
TES O
stimulated O
peroxynitrite O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine B
oxidase I
was O
identified O
as O
the O
likely O
source O
of O
TES O
stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O

superoxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
nitrotyrosine O
immunoblot O
experiments O
indicated O
that O
TES O
stimulated O
peroxynitrite O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine B
oxidase I
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O

butein O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein O
dependent O
HO-1 B
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O

butein O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK B
phosphorylation O
. O
These O
results O
indicate O
that O
butein O
may O
be O
used O
to O
prevent O
functional O
dental O
cell O
death O
and O
thus O
may O
be O
useful O
as O
a O
pulpal O
disease O
agent O
. O

Butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
(H2O2)-induced O
dental O
cell O
death O
. O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme B
oxygenase-1 I
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O

Butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
(H2O2)-induced O
dental O
cell O
death O
. O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 B
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant B
response I
elements I
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear B
factor-E2-related I
factor I
2 I
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
HO-1 B
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein O
induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O
may O
be O
used O
to O
prevent O
functional O
dental O
cell O
death O
and O
thus O
may O
be O
useful O
as O
a O
pulpal O
disease O
agent O
. O

Butein O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
(H2O2)-induced O
dental O
cell O
death O
. O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO B
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O

manumycin O
A O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
siRNA O
screening O
strategy O
, O
assay O
implementation O
and O
validation O
, O
data O
triaging O
, O
and O
example O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase O
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I B
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I O
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

manumycin O
A O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
siRNA O
screening O
strategy O
, O
assay O
implementation O
and O
validation O
, O
data O
triaging O
, O
and O
example O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase O
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I B
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

manumycin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
siRNA O
screening O
strategy O
, O
assay O
implementation O
and O
validation O
, O
data O
triaging O
, O
and O
example O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase B
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I O
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

manumycin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
siRNA O
screening O
strategy O
, O
assay O
implementation O
and O
validation O
, O
data O
triaging O
, O
and O
example O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase O
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I O
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β B
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O

compound O
C O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O

SB216763 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O

MG132 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK B
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme B
A I
carboxylase I
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β B
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O

Ursolic O
Acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated B
Protein I
Kinase I
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Aci O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O

Ursolic O
Acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen B
Synthase I
Kinase3 I
β I
Mediate O
Ursolic O
Aci O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK B
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β B
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
AMPK B
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β B
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O

ursolic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase B
3 I
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O

MG132 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 B
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 B
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

compound O
C O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase B
3 I
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O

SB216763 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase B
3 I
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O

ursolic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 B
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT B
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O

ursolic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR B
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O

compound O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK B
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O

SB216763 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β B
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O

MG132 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK B
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

MG132 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
enhanced O
phosphorylation O
of O
GSK3β B
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

quercetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O

quercetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 B
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O

Flavonoids O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O

catechins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O

quercetin O
glycosides O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 B
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O

estrone O
3-sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O

estrone O
3-sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 B
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O

dehydroepiandrosterone O
sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O

dehydroepiandrosterone O
sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 B
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O

DHEAS O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
( O
DHEAS O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O

DHEAS O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 B
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
( O
DHEAS O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 B
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 B
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O

quercetin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 B
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
querceti O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O

quercetin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 B
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
querceti O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O

epigallocatechin O
3-O-gallate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 B
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallat O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O

epigallocatechin O
3-O-gallate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 B
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallat O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O

epigallocatechin O
3-O-gallate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O

EGCG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
( O
EGCG O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O

EGCG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 B
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

